

DECLARATION

In the matter of U.S. Patent Application Ser. No. 10/070,387 in the name of Naoki MIDOH, et al.

I, Kyoko IMAMURA, of Kyowa Patent and Law Office, 2-3, Marunouchi 3-Chome, Chiyoda-Ku, Tokyo-To, Japan, declare and say:

that I am thoroughly conversant with both the Japanese and English languages; and,

that the attached document represents a true English translation of Japanese Patent Application No. 1999-253040 filed on September 7, 1999.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: October 13, 2004

Kyoko IMAMURA

Name of Document: Patent Application

Reference Number: PM1533

Application Date: September 7, 1999

To: The Commissioner of the Patent Office

International Patent Classification: C12N

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Naoki MIDOH

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Kaoru OKAKURA

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Koichi MIYAMOTO

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Manabu WATANABE

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Koji YANAI

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Tet

Tetsuya YASUTAKE

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Sato AIHARA

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Takafumi FUTAMURA

Inventor:

Address: c/o Technische Universitat Berlin,

Max-Volmer-Institut fur Biophysikalische Chemie Und Biochemie, Franklinstr. 29, D-10587 Berlin,

Germany

Name:

Horst Kleinkauf

Inventor:

Address: c/o I

c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Takeshi MURAKAMI

Applicant:

Identification Number: 000006091 Name: MEIJI SEIKA KAISHA, LTD. Representative: Ichiro KITAZATO

Tel.: 03-3273-3357

Indication of the Fee:

Account Number: 008305

Fee: 21,000 Yen

List of Documents filed:

Specification 1 copy Drawing 1 copy

Proofreading: Needed

[TITLE OF INVENTION] CYCLIC DEPSIPEPTIDE SYNTHETASE GENE [SCOPE OF CLAIMS]

[Claim 1]

A gene carrying the following DNA (a) or (b):

(a) DNA of a nucleotide sequence shown as SQ ID No. 1; (b) a microorganism-derived DNA hybridizing with the DNA of the nucleotide sequence (a) under stringent conditions and encoding a protein with cyclic depsipeptide synthetase activity.

[Claim 2]

A protein described below in (a) or (b):

- (a) a protein of an amino acid sequence shown as SQ ID No. 2; or
- (b) a protein of an amino acid sequence prepared through deletion, substitution or addition of one or several amino acids in the amino acid sequence (a) and with cyclic depsipeptide synthetase activity.

[Claim 3]

A recombinant vector carrying a gene according to claim 1.

[Claim 4]

A microorganism harboring a recombinant vector according to claim 3 and expressing the gene.

[Claim 5]

A microorganism according to claim 4, wherein the microorganism is a fungus producing the substance PF1022.

[Claim 6]

A method for producing the substance PF1022 and a derivative thereof by using a microorganism according to claim 4 or 5.

[DETAILED DESCRIPTION OF THE INVENTION]
[0001]

[Technical Field to which the Invention Belongs]

The present invention relates to the cyclic depsipeptide synthetase gene for producing the substance PF1022 as a cyclic depsipeptide with anthelmintic activity, a protein encoded by the gene, a recombinant vector using the gene, and a method for producing the substance PF1022 in a substance PF1022-producing microorganism integrated with the recombinant vector.

[0002]

[Prior Art]

The substance [cyclo(D-lactyl-L-N-PF1022 methylleucyl-D-3-phenyllactyl-L-N-methylleucyl-D-lactyl-L-N-methylleucyl-D-3-phenyllactyl-L-N-methylleucyl)] cyclic depsipeptide produced by a filamentous fungus of Agonomycetales, namely the strain PF1022 [Mycelia sterilia; the strain was deposited as FERM BP-2671 at National Institute of Bioscience and Human-Technology, Agency of Industrial Science Technology, Japan]. The substance PF1022 exerts an extremely high anthelmintic activity on nematodes parasitic on animals [Japanese Patent publication No. 35796/1991; Sasaki, T. et al., J. Antibiotics., 45, 692 (1992)]. Therefore, the substance is useful as an anthelmintic for animals and is additionally useful as a raw material for the synthesis of a more highly active derivative of the substance. [0003]

The amounts of secondary metabolites produced by microorganisms and separated from natural origins are generally very slight. So as to industrially utilize such metabolites, therefore, the productivity of the secondary metabolites is necessarily increased. For the increase of the productivity, the examination of the culturing methods and the culture medium

components, the modification of the fermentation conditions such as addition of the precursors, and the mutation of the strains by ultraviolet irradiation or mutagen are carried out. In recent years, the productivity has been increased by utilizing gene recombinant technology in addition to the aforementioned methods.

[0004]

As the method, the enhancement of the expression of the genes of enzymes involved in the biosynthetic pathways, the enhancement of the expression of the genes involved in the control of the biosynthesis, and blockage of unnecessary biosynthetic pathways and the like are practically effected [Khetan, A. and Hu, W.-S. Manual of Industrial Microbiology and Biotechnology 2nd edition, p. 717, (1999)]. As a specific example, further, it has been known a method for improving the productivity, comprising allowing the hemoglobin gene of a bacterium to be expressed for the purpose of the improvement of the oxygen usability [Minas, W. et al., Biotechnol. Prog. 14, 561, (1998)].

[0005]

The most general means for the improvement of the productivity by gene recombinant technology is the enhancement of the expression of the genes of enzymes involved in biosynthetic pathway. For the application of the means, essentially, transformation method the of subject microorganism is established; a promoter and a terminator applicable to the enhancement of the expression are to be present; and the biosynthetic pathway is to be elucidated and their genes are to be isolated. The transformation method of a fungus producing the substance PF1022, comprising integrating a foreign gene, has already been established (WO 97/00944); and also, a report concerning the promoter and terminator

applicable to the enhancement of the expression has been issued (Japanese Patent Application No. 252851/1999). However, no gene involved in the biosynthetic pathway has been isolated. [0006]

substance PF1022 is of a structure comprising L-N-methylleucine, D-lactic acid, and D-phenyllactic acid, which are bonded together through ester bonds and amide bonds. It is considered that the substance is synthesized from 4 molecules of L-leucine, 2 molecules of D-lactic acid and 2 molecules of D-phenyllactic acid by a certain peptide synthetase in a fungus producing the substance. Peptide synthetase means an enzyme involved in the biosynthesis of microbial secondary metabolites, such as peptide, depsipeptide, lipopeptide and peptide lactone, from substrates of amino acids and hydroxy acid. The sequences of some peptide synthetases have already been elucidated [Marahiel, M. A. et al., Chem. Rev., 97, 2651, (1997)]. The reaction with such enzyme is totally different from the synthetic system of protein with ribosome using mRNA as template. Peptide synthetase has one domain for each substrate, where each substrate is activated with ATP for binding through phosphopantothenic acid in the domain; and the resulting bound substrates form amide bonds or ester bonds due to the catalytic actions in the regions between the individual domains.

[0007]

[Problem to be solved by the invention]

The cyclic depsipeptide synthetase gene capable of improving the productivity of the substance PF1022 is provided, by permitting excess expression thereof in a fungus producing the substance PF1022.

[8000]

[Means for Solving the Problem]

So as to overcome the problem, the inventors isolated the cyclic depsipeptide synthetase gene for the synthesis of the substance PF1022 from a fungus producing the substance PF1022, on the basis of the sequence of the conserved region of a known peptide synthetase. Furthermore, the inventors successfully improved the productivity of the substance PF1022 by preparing an expression vector modified with the promoter and terminator of the gene and integrating the expression vector in the fungus producing the substance PF1022. Thus, the invention has been achieved.

[0009]

More specifically, the invention relates to the following aspects.

- 1. A gene carrying the following DNA (a) or (b):
 - (a) DNA of a nucleotide sequence shown as SQ ID No. 1; or
- (b) a microorganism-derived DNA hybridizing with the DNA of the nucleotide sequence (a) under stringent conditions and encoding a protein with cyclic depsipeptide synthetase activity.
- 2. A protein described below in (a) or (b):
- (a) a protein of an amino acid sequence shown as SQ ID No. 2; or
- (b) a protein of an amino acid sequence prepared by deletion, substitution or addition of one or several amino acids in the amino acid sequence (a) and with cyclic depsipeptide synthetase activity.
- 3. A recombinant vector carrying a gene in a first aspect of the invention.
- 4. A microorganism harboring a recombinant vector in a third aspect of the invention and expressing the gene.
- 5. A microorganism in a fourth aspect of the invention, wherein the microorganism is a fungus producing the substance PF1022.

6. A method for producing the substance PF1022 and a derivative thereof by using a microorganism in a fourth or fifth aspect of the invention.

[0010]

[Mode for Carrying out the Invention]

The cyclic depsipeptide synthetase gene of the invention can be isolated from a fungus producing the substance PF1022 for example by the following method.
[0011]

A library comprising the genomic DNA of a fungus producing the substance PF1022 is prepared by extracting the genomic DNA from the fungus producing the substance PF1022, cleaving the DNA with an appropriate restriction endonuclease, and subsequently ligating to a phage vector.

Based on the conserved region of the amino acid sequence of a known peptide synthetase and a partial amino acid sequence of the cyclic peptide synthetase purified from the fungus producing the substance PF1022, an appropriate primer is synthesized, which is used to effect polymerase chain reaction (PCR) with the genomic DNA derived from the fungus producing the substance PF1022 as template, to amplify a DNA fragment of the cyclic peptide synthetase gene. Using the DNA fragment as probe, the genome library is screened. In such manner, the whole region of the cyclic peptide synthetase gene can be isolated. After the determination of the nucleotide sequence of the DNA fragment, appropriate restriction cleavage sites are introduced upstream the translation initiation codon and downstream the translation termination codon by means such as PCR, to recover a gene fragment singly containing the cyclic peptide synthetase gene.

[0012]

The gene of the invention encompasses a nucleotide

sequence hybridizable with the thus determined nucleotide sequence under stringent conditions. Using routine methods (for example site-directed mutagenesis) in the field of genetic engineering, additionally, DNA fragments with modification of the gene, such as addition, insertion, deletion or substitution of the gene, can be encompassed within the scope of the invention. The stringent conditions herein referred to mean that the rinsing procedure of the membrane after hybridization is carried out in solutions at low salt concentrations and high temperature, for example, a condition such that rinsing is effected in 0.2 x SSC (1 x SSC: 15 mM citrate trisodium, 150 mM sodium chloride) - 0.1% SDS solution at 60°C for 15 minutes.

A promoter is conjugated upstream the cyclic peptide synthetase gene isolated by the method, while a terminator is conjugated downstream the cyclic peptide synthetase gene; additionally, selective marker genes such as nutrient auxotrophic complementary genes or/and genes with chemical resistance are conjugated thereto, to prepare a recombinant vector for gene expression.

[0014]

The selective markers for use in recombinant vectors for gene expression include for example nutrient auxotrophic complementary genes such as pyrG, argB, trpC, niaD, TRP1, LEU2 and URA3; and genes with chemical resistance against destomycin, benomil, oligomycin, hygromycin, G418, bleomycin, fleomycin, phosphinothricin, ampicillin, and kanamycin.
[0015]

The conjugation of the promoter and terminator to the inventive gene and the insertion thereof into a vector can be carried out by methods known per se. The promoter and terminator for use in accordance with the invention are not

specifically limited, and include for example, genes of glycolytic enzymes, such as 3-phosphoglycerate kinase, glycelaldehyde-3-phosphate dehydrogenase and enolase; genes of amino acid synthesis, such as ornithine carbamoyltransferase and tryptophan synthase; genes of hydrolases, such as amylase, protease, lipase, cellulase and acetoamidase; genes of oxidoreductases, such as nitrate reductase, orotidine-5'-phosphate dehydrogenase, and alcohol dehydrogenase; and genes of bacteria producing the substance PF1022, which are highly expressed in the fungus producing the substance PF1022, such as Abp1.

[0016]

The transformation of a host with a recombinant vector prepared in such manner and the culturing of the resulting transformant enable prominent production of the substance PF1022. For a host with no synthesis of \underline{L} -leucine, \underline{D} -lactic acid or \underline{D} -phenyllactic acid as a substrate for the cyclic depsipeptide synthetase of the invention, additionally, the host is cultured after addition of deficient substrates or derivatives thereof, whereby the substance PF1022 or derivatives thereof can be produced. The invention also encompasses the culturing of the transformant in a culture medium to collect the substance PF1022 or a derivative thereof from the resulting microorganisms.

[0017]

As the host for use, appropriate bacteria or fungal microorganisms usable as hosts for gene recombination can be used, with no specific limitation. Preferably, the host is Escherichia coli, a bacterium of the genus Bacillus, an actinomycetes, yeast and a filamentous fungus; more preferably, the host is a filamentous fungus producing the substance PF1022; and most preferably, the host is the strain PF1022 (Mycelia

sterilia, FERM BP-2671).
[0018]

[0019]

The transformation of such host can be carried out by methods known per se. For example, the introduction of a recombinant vector for gene expression into a host can be carried out by routine methods, for example electroporation process, polyethylene glycol process, <u>Agrobacterium</u> process, lithium process, calcium chloride process and the like, with no specific limitation.

The transformant can also be cultured by general methods, by appropriately selecting culture media and culturing conditions and the like. As the culture media, use can be made of routine components, such as carbon sources for example glucose, sucrose, thick malt syrup, dextrin, starch, glycerol, molasses, animal and vegetable oils and the like. As the nitrogen source, additionally, use can be made of soy bean powder, wheat germ, pharmamedia, corn steep liquor, cotton seed bran, meat extract, polypeptone, malt extract, yeast extract, sodium nitrate, urea and the ammonium sulfate, Additionally, it is effective to add inorganic salts capable of generating sodium, potassium, calcium (calcium carbonate and the like), magnesium, cobalt, chloride, phosphorus (dipotassium hydrogen phosphate), sulfuric acid (magnesium sulfate and the like) and other ions, if necessary. Ιf necessary, furthermore, selective chemical agents including various vitamins such as thiamine (thiamine chloride salt and the like), amino acids such as glutamic acid (sodium glutamate and the like) and asparagine (DL-asparagine and the like), trace nutrients such as nucleotide and antibiotics can be added. Organic materials and inorganic materials supporting fungal growth and promoting the production of the substance PF1022 or

a derivative thereof can appropriately be added. [0020]

The pH of the culture medium is about pH 6 to pH 8. As the culturing method, agitation culture, aerated agitation culture or submerged aerobic culture under aerobic conditions can be carried out. Particularly, submerged aerated culture is the most appropriate. The temperature appropriate for culturing is 15°C to 40°C. In many cases, the microorganism grows around 26°C to 37°C. The production of the substance PF1022 or a derivative thereof varies, depending on the culture medium and culture conditions or the host used, but the accumulation thereof generally reaches the peak in 2 days to 25 days by any of the culture methods. Just when the amount of the substance PF1022 or a derivative thereof reaches the peak, the culturing is terminated, to isolate and purify the objective substance from the culture.

[0021]

So as to recover the substance PF1022 or a derivative thereof from the culture, general separation means utilizing the characteristic properties, for example solvent extraction method, ion exchange resin method, adsorption or partition column chromatography method, gel filtration method, dialysis method, precipitation method and crystallization method, can be used singly or in appropriate combinations thereof to extract and purify the substance PF1022 or a derivative thereof. From the culture, for example, the substance PF1022 or a derivative thereof is extracted in acetone, methanol, butanol, ethyl acetate, butyl acetate and the like. So as to further purify the substance PF1022 or a derivative thereof, chromatography using Sephadex LH-20 (Pharmacia Co.) or Toyopearl HW-40 (Toso, Co.) is satisfactorily effected. By the methods described above or combinations thereof, the substance PF1022 or a

derivative thereof can be recovered in purity. [0022]

[Examples]

The present invention will now be described in the following examples, but the invention is not limited to them. [0023]

Example 1

Cloning of cyclic depsipeptide synthetase gene from a fungus producing the substance PF1022

Genomic DNA isolation and preparation of genome library With UV irradiation or NTG treatment, mutation was induced into the fungus (Mycelia sterilia; FERM BP-2671) producing the substance PF1022, to prepare a fungal strain 432-26 producing the substance PF1022 and having an improved productivity of PF1022, from which the genome DNA was extracted. The fungal strain 432-26 producing the substance PF1022 was cultured in 50-m1 of a seed culture medium [1 % yeast extract, 1 % malt extract, 2 % polypeptone, 2.5 % glucose, 0.1 % dipotassium hydrogen phosphate, 0.05 % magnesium sulfate (pH 7.0)] at 26°C for 2 days, to recover the fungi by centrifugation. The resulting fungi were frozen in liquid nitrogen and ground in a mortar with a pestle. From the ground fungi, the genome DNA was isolated by ISOPLANT (Nippon Gene, Co.) according to the attached protocol. The isolated genome DNA was partially digested with Sau3A I, to recover DNA fragments of 15 kb to 20 kb by agarose gel electrophoresis, which were then treated with alkali phosphatase to dephosphorylate the termini of the DNA fragments. The DNA fragments were inserted in a phage vector Lambda DASH II (STRATAGENE, CO.). The recombinant phage vector recovered in such manner was subjected to in vitro packaging with Gigapack III Gold Packaging Extract (STRATAGENE CO.) according to the attached protocol. Subsequently,

recombinant phage grew on the host <u>Escherichia coli</u> strain XL1-Blue MRA (P2) for plaque formation on a plate.
[0024]

2. Isolation of partial DNA fragment of cyclic depsipeptide synthetase gene

A known peptide synthetase was subjected to multiple alignment, so that WTSMYDG and VVQYFPT were detected as excellently conserved regions. Based on these sequences, 5'-TGGACIWSNATGTAYGAYGG-3' (SQ primers IDNO. 3) and 5'-GTIGGRAARTAYTGIACNAC-3'(SQ ID NO. 4) were synthesized. Using these primers, the genome DNA isolated from the fungus producing the substance PF1022 was used as template for PCR. Using 50 ng of the genome DNA as template, 1 .25 units ExTaq DNA polymerase (TaKaRa Brewery, Co.), the attached buffer and dNTP mixture, and 10 µM primer in 50 µl of a reaction solution, PCR was conducted under the following conditions: 94°C for 3 minutes [94°C for one minute, 65°C (with 0.5°C decrement per one cycle) for one minute, 72°C for one minute] x 30 times and 72°C for 3 minutes. Through the reaction, a DNA fragment of about 350 bp was amplified; and the resulting DNA fragment was inserted in pCR2.1 plasmid vector, by using Original TA Cloning Kit (Invitrogen Co.) according to the attached protocol. [0025]

The nucleotide sequence of the thus cloned DNA fragment was determined, by using DNA sequencing Kit dRhodamine Terminator Cycle Sequencing Ready Reaction (Perkin Elmer Co.) and ABI PRISM 310 Genetic Analyzer (Perkin Elmer Co.) according to the attached protocol. Consequently, the nucleotide sequence of the isolated DNA fragment was homologous to the peptide synthetase gene, which apparently indicates that the DNA fragment was a part of the objective cyclic depsipeptide synthetase gene.

[0026]

3. Cloning of the whole region of the cyclic depsipeptide synthetase gene

The probe for use in the screening of the genome library was prepared, by PCR to allow the DNA fragment to incorporate fluorescein-labeled dUTP. By using pCR2.1 plasmid vector inserted with 100 ng of the DNA fragment of the cyclic depsipeptide synthetase gene as template, 1.25 units ExTaq DNA polymerase (TaKaRa Brewery, Co.) and the attached buffer, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.02 mM dTTP, 0.18 mM fluorescein-labeled dUTP (FluoroGreen; Amersham Co.) and 10µM primers (SQ ID Nos. 3 and 4) in 50 µl of a reaction solution, PCR was carried out under the following conditions: 94°C for 2 minutes, (94°C for 30 seconds, 55°C for one minute and 72°C for one minute) x 25 times, 72°C for 3 minutes. Through the reaction, a fluorescein-labeled probe of about 350 bp was prepared.

[0027]

On the plate with formed plaques as prepared in Example 1.1, Hybond-N+ membrane (Amersham Co.) was mounted, to deposit the plaques. The membrane was treated with an alkali, to denature the recombinant phage DNA on the membrane into a single strand and thereby adsorb the DNA on the membrane. The phage DNA-adsorbed membrane was placed in a buffer prepared by using Hybridization Buffer Tablets (Amersham Co.), for incubation at 60°C for one hour. The fluorescein-labeled probe was denatured and added to the resulting incubation mixture, for overnight hybridization at 60°C. Thereafter, the membrane was rinsed in 1 x SSC (SSC: 15 mM citrate trisodium, 150 mM sodium chloride) -0.1 % SDS solution at 60°C for 15 minutes and further rinsed in 0.2 x SSC-0.1 % SDS solution at 60°C for 15 minutes. The

fluorescein-bound plaque was visualized by using DIG-wash and (Boehringer Mannheim, block buffer alkali set Co.), phosphatase-labeled anti-fluorescein antibody (Antifluorescein-AP, Fab fragment, Boehringer Mannheim Co.), a substrate chloride chromogenic nitroblue tetrazolium (Boehringer Mannheim Co.) and X-phosphate (Boehringer Mannheim Co.) according to the attached protocol. In such manner, a positive clone carrying the 5' upstream region and 3' downstream region of a region homologous to the probe was screened. [0028]

Determination of the nucleotide sequence 4. The DNA fragment in the positive clone thus isolated was amplified by PCR using primers 5'-GCGGAATTAACCCTCACTAAAGGGAACGAA-3' (SQ ID No. 5) and 5'-GCGTAATACGACTCACTATAGGGCGAAGAA-3' (SQ ID No. 6) as the phage vector sequences. Using 100 ng of the positive clone DNA as template, 2.5 units LA Taq DNA polymerase (TaKaRa Brewery, Co.), the attached buffer and dNTP mixture, 2.5 mM magnesium chloride, and 0.2 µM primer in a reaction solution of 50µl, PCR was effected under the following conditions: 94°C for one minute, (98°C for 10 seconds and 68°C for 15 minutes) x 25 times, 72°C for 15 minutes. The resulting PCR product was purified and treated with a nebulizer, to be decomposed randomly into fragments of 0.5 kb to 2.0 kb. The termini of the resulting fragments were blunt ended with T4 DNA polymerase and phosphorylated with T4 polynucleotide kinase, to be then inserted at the EcoRV site of pT7Blue (Novagen Co.) for insertion in Escherichia coli strain JM109. 168 colonies thus prepared were directly subjected to PCR using M13 Primer M4 (TaKaRa Brewery, Co.) and M13 primer RV (TaKaRa Brewery, Co.) and were then purified, which were then sequenced by using M13 primer M4 (TaKaRa Brewery, Co.). Using 1.25 units ExTaq DNA polymerase (TaKaRa Brewery,

Co.), the attached buffer and dNTP mixture, and 0.5 µM primer, PCR was effected in 50 µl of a reaction solution under the following conditions: 94°C for 4 minutes, (94°C for 30 seconds, 55°C for 30 seconds and 72°C for 2 minutes) x 30 times, 72°C for 3 minutes. Additionally, sequencing was effected, by using DNA Sequencing Kit dRhodamine Terminator Cycle Sequencing Ready Reaction (Perkin Elmer Co.) and ABI PRISM 310 Genetic Analyzer (Perkin Elmer Co.) according to the attached protocol.

Based on the results, an insufficiently analyzed region was amplified by PCR using a primer newly designed on the basis of the analyzed nucleotide sequence and was then purified. Using the primer used for PCR, the region was sequenced, whereby the 15606-bp nucleotide sequence of the DNA fragment in the positive clone was determined.
[0030]

The analysis of the sequence apparently indicates that an open reading frame (ORF) of 9633 bp was present and a protein speculated from the sequence comprised 3210 amino acid residues of 353 kDa and that the protein was homologous to the peptide synthetase. Additionally, the protein with the highest homology was enniatin synthetase (S39842) with 56 % homology. The nucleotide sequence and amino acid sequence of the ORF of the cyclic depsipeptide synthetase gene thus isolated in accordance with the invention are shown as SQ ID Nos. 1 and 2, respectively in the sequence listing.

[0031]

Example 2

Improvement of PF1022 productivity due to the excess expression of cyclic depsipeptide synthetase gene

1. Construction of recombinant vector for gene expression (Figure 1)

From the positive clone recovered in Example 1. 3, plasmid pPF7 was prepared by cleaving the inserted DNA fragment with NotI and inserting the DNA fragment into the NotI site of the pBluescriptII KS+ (STRATAGENE CO.). pPF7 was cleaved with BanIII and SmaI and electrophoresed on agarose gel, to recover a DNA fragment of about 8250 by from the agarose gel. The fragment was inserted in pBluescriptII KS+, to prepare plasmid pPF7-1.

[0032]

Using pPF7 template, 5'as AGCATCGGATCCTAACAATGGGCGTTGAGCAGCAAGCCCTA-3' (SQ ID No. 7; designed for the initiation of the translation at the 9th Met from terminus the of the N ORF) 5'or AGCATCGGATCCTAACAATGTCAAACATGGCACCACTCCCTA-3' (SQ ID No. 13; designed for the initiation of the translation at the first Met from the Ν terminus of the ORF), 5'and TTTGCTTCGTACTCGGGTCCT-3'(SQ ID No. 8) as primers for the amplification of a region of about 440 bp (using SQ ID Nos. 7 and 8) or a region of about 470 bp (using SQ ID Nos. 13 and 8) the around terminus N the to BanIII site, and 5'-GCATCGCGATACTAGAGAAG-3' (SQ ID No. 9) 5 **'** – and AGCATCGAATTCGGATCCCTAAACCAACGCCAAAGCCCGAAT-3' (SQ ID No. 10) as primers for the amplification of a region of about 920 bp from the Small site to the C terminus, PCR was effected. Then, the primers were designed so as to insert the BamHI site at the 5' and 3' sites of the inventive cyclic depsipeptide synthetase gene. Using 150 ng of the plasmid DNA as template, 2.5 units KOD DNA polymerase (Toyo Boseki), the attached buffer and dNTP mixture, 1 mM magnesium chloride, and 0.5 µM primer in 50 µl of a reaction solution, PCR was effected under the following conditions: 98°C for 30 seconds, (98°C for 15 seconds, 65°C for 2 seconds, 74°C for 30 seconds) x 10 times, 74°C for one minute.

The PCR reaction solutions recovered by using the individual primers were precipitated with ethanol, to recover PCR products. Concerning the N terminal region, the N terminal region was cleaved with BamHI and BamIIII; concerning the C terminal region, the C terminal region was cleaved with SmaI and BamHI. Thereafter, the resulting fragments were electrophoresed on agarose gel, to recover DNA fragments from the agarose gel. [0033]

The PCR fragment of the C terminal region was inserted in the SmaI and BamHI sites of pPF7-1, to prepare plasmid pPF7-2. cleaved with plasmid The was BanIII BamHI and and electrophoresed on agarose gel, to recover a DNA fragment of about 9170 bp from the agarose gel. The DNA fragment and the N terminal region prepared by using SQ ID Nos. 7 and 8 were simultaneously inserted in the BamHI site of pBluescript II KS+, to reconstruct the cyclic depsipeptide synthetase gene of the invention and prepare plasmid pPFsyn (initiating the translation at the 9th Met from the N terminus of the ORF). [0034]

Alternatively, an about 9170-bp DNA fragment cleaved from pPF7-2 and the N-terminal region prepared by using SQ ID Nos. 7 and 13 were simultaneously inserted in the BamHI site of pHSG299 (TaKaRa Brewery Co.), to reconstruct the cyclic depsipeptide synthetase gene of the invention and prepare plasmid pPFsynN (initiating the translation at the first Met from the N terminus of the ORF). In such manner, the cyclic depsipeptide synthetase gene with the BamHI sites on both the termini was prepared.

[0035]

Herein, Escherichia coli transformed with the plasmid pPFsyn (Escherichia coli DH5α) was deposited with Accession No. FERM P-17541 at National Institute of Bioscience and

Human-Technology, Agency of Industrial Science and Technology, supra.

[0036]

Additionally, <u>Escherichia coli</u> transformed with the plasmid pPFsynN (<u>Escherichia coli</u> DH5α) was deposited with Accession No. FERM P-17542 at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, supra.

[0037]

pPFsyn or pPFsynN was cleaved with <u>Bam</u>HI. Subsequently, the cyclic depsipeptide synthetase gene region was recovered from the individual gels. The gene region was inserted at the <u>Bam</u>HI site of pABPd with the promoter and terminator of <u>Abpl</u> gene described in Japanese Patent Application No. 252851/1999, to prepare an expression vector pABP/PFsyn (initiating the translation at the 9th Met of the N terminus of ORF) and an expression vector pABP/PFsynN (initiating the translation at the first Met of the N terminus of ORF) as the expression vectors for expressing the cyclic depsipeptide synthetase gene of the invention.

[0038]

2. Introduction and expression of cyclic depsipeptide synthetase gene in fungus producing the substance PF1022
The expression vectors were introduced in a fungus producing the substance PF1022 (Mycelia sterilia; FERM BP-2671) according to the method of Example 1 described in WO 97/00944, to screen strains with high resistance against hygromycin B. The introduction of the objective gene in these strains was confirmed by PCR using a primer 5'-TGATATGCTGGAGCTTCCCT-3' (SQ ID No. 11) prepared from the sequence of Abpl promoter and a primer 5'-GCACAACCTCTTTCCAGGCT-3' (SQ ID No. 12) prepared from the sequence of the cyclic depsipeptide synthetase gene. In

such manner, gene-introduced strains with high resistance against hygromycin B and with the inventive cyclic depsipeptide synthetase gene introduced therein were screened.
[0039]

The gene-introduced strains and the parent strain (Mycelia sterilia; FERM BP-2671) were separately cultured in 50 ml of a seed culture medium at 26°C for 2 days; 1 ml of each of the cultures was inoculated separately in a generation culture medium [6 % thick malt syrup, 2.6 % starch, 2 % wheat germ, 1 % pharmamedia, 0.2 % magnesium sulfate 7 hydrates, 0.2 % calcium carbonate, 0.3 % sodium chloride (pH 7.5)] and cultured therein at 26°C for 4 days. The resulting culture was centrifuged at 4500 rpm for 5 minutes to harvest the fungus; the resulting individual fungus species were rinsed in 0.3 M potassium chloride. The individual fungal species were frozen in liquid nitrogen and freeze-dried.

The following extraction procedure was carried out on ice or in a low-temperature chamber at 4°C. Into a 2-ml tube containing 10 mg of the freeze-dried fungal species and 1.0 ml of glass beads (0.5-mm diameter) was added 1.0 ml of an extraction buffer [50 mM Tris-HC1 (pH 8.0), 0.3 M potassium chloride, 60 % glycerol, 10 mM ethylenediaminetetraacetate disodium, 5 mM dithiothreitol, 10 µM leupeptin, 1 mM phenylmethanesulfonic acid, 60 µg/ml chimostatin]. The microtube was set in a Mini-Bead-Beater-8 (Biospec, Co.), which was then driven at the maximum speed for 3 minutes for extraction. The resulting mixture was centrifuged at 15000 rpm for 5 minutes; 100 µl of the supernatant was charged in and mixed with 100 μl of 10 % trichloroacetic acid solution. After the solution was left to stand for 15 minutes, the solution was centrifuged at 15000 rpm for 10 minutes. The resulting

precipitate was dissolved in 15 µl of an alkali solution (2 % sodium carbonate, 0.4 % sodium hydroxide), to which was added 60 μl of a sample buffer [125 mM Tris-HC1 (pH 6 . 8), 20 % glycerol, 4 % sodium dodecylsulfate, 10 % 2-mercaptoethanol, 50 mg/1 This was heated in boiling water for 5 bromophenol blue]. then electrophoresed minutes, and was [Sodium Dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)] on 4 % to 20 % polyacrylamide gel with an electrophoresis system (Tefco Co.). The polyacrylamide gel after electrophoresis was stained by using Quick-CBB (Wako Pure Chemical Co.) according to the attached protocol. The electrophoresis result of the proteins extracted from the parent strain and the gene-introduced strain with pABP/PFsyn is shown in Figure 2. [0041]

As described above, the expression level of the cyclic depsipeptide synthetase in the gene-introduced strains was distinctively higher than the level in the parent strain.

[0042]

Extraction and assay of the substance PF1022 3. gene-introduced strains and the parent strain were The separately cultured in 50 ml of a seed culture medium at 26°C for 2 days; and 1 ml of each of 50 ml of the cultures was inoculated separately in a generation culture medium and cultured therein at 26°C for 6 days. 10 ml each of the cultures was placed and centrifuged at 3000 rpm for 10 minutes; and the resulting strains were harvested separately. 10 ml of methanol was added to the individual strains, which were vigorously shaken and left to stand for 30 minutes. Thereafter, those were again shaken and centrifuged at 3000 rpm for 10 minutes; the substance PF1022 extracted from the individual strains in the supernatant was assayed by liquid chromatography. column, LiChrospher 100 RP-18 (e) (Kanto Chemical CO.) was used;

the column temperature was 40°C ; the mobile phase was 80 % acetonitrile at a flow rate of 1.0 ml/min; the substance PF1022 was detected on the basis of the absorbance at 210 nm. The retention time of the substance PF1022 under the conditions was 5 minutes to 6 minutes. The experiments were carried out in duplicate. The average values of the assay results of the substance PF1022 extracted from the parent strain and the gene-introduced strain with the pABP/PFsyn are shown in Table 1.

[0043]

[Table 1]

Substance PF1022 (µg/ml)

Parent strain

88

Gene-introduced strain

222

[0044]

The substance PF1022 productivity of the gene-introduced strain was about 2.5-fold that of the parent strain. It is apparently shown that the excess expression of the inventive cyclic depsipeptide synthetase elevates the productivity of the substance PF1022.

[0045]

[ADVANTAGEOUS EFFECTS OF THE INVENTION]

The introduction of the inventive cyclic depsipeptide synthetase gene in the fungus producing the substance PF1022 can improve the productivity of the substance PF1022.

[0046]

[SEQUENCE LISTING]

<110> Meiji Seika Kaisha, Ltd

<120> Cyclodepsipeptide synthetase gene

<130> PM1533

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 9633

<212> DNA

<213> Mycelia sterilia

<220>

<221> CDS

<222> (1).. (9633)

<223> peptide synthetase for PF1022

<220>

<221> mat#peptide

<222> (13).. (9630)

<400> 1

atg tca aac atg gca cca ctc cct acg atg ggc gtt gag cag caa gcc 48

Met Ser Asn Met Ala Pro Leu Pro Thr Met Gly Val Glu Gln Gln Ala

-1 1 5 10

cta tca ctt tca tgc ccc tta ctc cct cat gac gat gag aaa cac tca 96 Leu Ser Leu Ser Cys Pro Leu Leu Pro His Asp Asp Glu Lys His Ser

15 20 25

gac aac ctt tac gag caa gca act cgg cac ttc ggc ttg agc cga gac 144
Asp Asn Leu Tyr Glu Gln Ala Thr Arg His Phe Gly Leu Ser Arg Asp

30 35 40

aag atc gaa aat gtc tta cca tgt act tcc ttt caa tgt gat gtc ata 192 Lys Ile Glu Asn Val Leu Pro Cys Thr Ser Phe Gln Cys Asp Val Ile

45 50 55 60

gat tgc gcc gtc gac gat cgg cgg cat gct atc ggt cac gtc gtc tat 240 Asp Cys Ala Val Asp Asp Arg Arg His Ala Ile Gly His Val Val Tyr

65 70 75

gat atc ccc aat aca gtg gac atc cag cgt tta gcc gca gcc tgg aaa 288
Asp Ile Pro Asn Thr Val Asp Ile Gln Arg Leu Ala Ala Ala Trp Lys

80 85 90

gag gtt gtg cgg cag aca cca atc ttg agg acc ggc atc ttt aca tca 336 Glu Val Val Arg Gln Thr Pro IIe Leu Arg Thr Gly IIe Phe Thr Ser

95 100 105

gaa acc ggc gac tot tit cag atc gtc tig aaa gaa ggc tgc cta ccg 384 Glu Thr Gly Asp Ser Phe Gln Ile Val Leu Lys Glu Gly Cys Leu Pro 110

115

120

tgg atg tac gcg aca tgt ctc ggc atg aag ggg gca gtg ata caa gat 432

Trp Met Tyr Ala Thr Cys Leu Gly Met Lys Gly Ala Val Ile Gln Asp

125 130 135 140

gaa gca gtc gcc gct atg act gga ccg cgt tgc aat cga tat gtc gtc 480 Glu Ala Val Ala Met Thr Gly Pro Arg Cys Asn Arg Tyr Val Val

145 150 155

ctg gag gac ccg agt acg aag caa agg ctg ctc atc tgg aca ttc agc 528

Leu Glu Asp Pro Ser Thr Lys Gln Arg Leu Leu Ile Trp Thr Phe Ser

160 165 170

cat gct tta gtg gat tat aca gtc cag gaa cgc atc ctt cag cgg gtt 576

His Ala Leu Val Asp Tyr Thr Val Gln Glu Arg Ile Leu Gln Arg Val

175

180

185

ctc aca gta tac gac ggc cgg gac gtc gag tgc cct cgc atc aag gat 624 Leu Thr Val Tyr Asp Gly Arg Asp Val Glu Cys Pro Arg Ile Lys Asp

190

195

200

aca gaa cat gtc tct cgg ttt tgg caa caa cac ttt gaa ggc tta gat 672

Thr Glu His Val Ser Arg Phe Trp Gln Gln His Phe Glu Gly Leu Asp

205

210

220

gcc tcc gta ttt ccc ctt cta cca tct cac cta act gtg tgc aat ccc 720

Ala Ser Val Phe Pro Leu Leu Pro Ser His Leu Thr Val Cys Asn Pro

225

230

235

aat gcg cgc gca gaa cat cat atc tca tac acg gga cca gtc cag agg 768 Asn Ala Arg Ala Glu His His Ile Ser Tyr Thr Gly Pro Val Gln Arg

240 245 250

aag tgg tcc cat aca agt atc tgt cgg gct gca ctc gca gtt ctt cta 816 Lys Trp Ser His Thr Ser Ile Cys Arg Ala Ala Leu Ala Val Leu Leu

255 260 265

tct cgc ttt aca cac tct tcg gag gcc ctc ttc ggt gtt gtg aca gaa 864 Ser Arg Phe Thr His Ser Ser Glu Ala Leu Phe Gly Val Val Thr Glu

270 275 280

Caa tot cac aac too gag gac caa aga cgg toa att gat ggc coc gca 912 Gln Ser His Asn Ser Glu Asp Gln Arg Arg Ser Ile Asp Gly Pro Ala agg aca gta gtg cct atc cgc gtc ctt tgt gcc cca gat caa tat gtg 960 Arg Thr Val Val Pro Ile Arg Val Leu Cys Ala Pro Asp Gln Tyr Val

tcg gat gtc att ggg gca atc acc gca cac gaa cac gcc atg cgc ggg 1008 Ser Asp Val Ile Gly Ala Ile Thr Ala His Glu His Ala Met Arg Gly

ttt gag cac gct gga ctt cgc aat atc cgc cgt acc gga gac gac ggg 1056 Phe Glu His Ala Gly Leu Arg Asn Ile Arg Arg Thr Gly Asp Asp Gly

tct gct gct tgt gga ttc cag acc gtg cta ctg gtg act gac ggt gat 1104
Ser Ala Ala Cys Gly Phe Gln Thr Val Leu Leu Val Thr Asp Gly Asp

355

350

360

gct ccc aag acc cct ggg agt gta ctt cat cga agt gta gaa gaa tcg 1152

Ala Pro Lys Thr Pro Gly Ser Val Leu His Arg Ser Val Glu Glu Ser

365 370 375 380

Asp Arg Phe Met Pro Cys Ala Asn Arg Ala Leu Leu Leu Asp Cys Gln

385

390

395

atg gct ggc aac tcg gca tcc cta gtc gca cga tat gat cat aat gtg 1248

Met Ala Gly Asn Ser Ala Ser Leu Val Ala Arg Tyr Asp His Asn Val

400 405 410

atc gac cca cgc cag atg tct cgc ttc ctg cga cag cta gga tac ctg 1296

Ile Asp Pro Arg Gln Met Ser Arg Phe Leu Arg Gln Leu Gly Tyr Leu

415 420 425

atc caa caa ttt cat cat cac gtc gat ctg cct ctg gtc aaa gaa ctg 1344

Ile Gln Gln Phe His His His Val Asp Leu Pro Leu Val Lys Glu Leu

430 435 440

Asp Val Val Thr Ala Glu Asp Cys Ala Glu Ile Glu Lys Trp Asn Ser

445 450 455 460

gaa cgc cta aca atg caa gac gcc tta atc cac gac acc ata tcc aag 1440

Glu Arg Leu Thr Met Gln Asp Ala Leu Ile His Asp Thr Ile Ser Lys

470

465

475

tgg gct gct ggc gat ccc aac aaa gct gca gtt ttc gct tgg gat ggg

1488

Trp Ala Ala Gly Asp Pro Asn Lys Ala Ala Val Phe Ala Trp Asp Gly

480

485

490

gaa tgg aca tac gcc gag cta gac aac ata tcc tcc cgt ctc gcc gtg 1536 Glu Trp Thr Tyr Ala Glu Leu Asp Asn Ile Ser Ser Arg Leu Ala Val

495

500

505

tat atc caa tcc ctg gac ttg aga cca gga caa gca ata ctc cca ctc 1584 Tyr Ile Gln Ser Leu Asp Leu Arg Pro Gly Gln Ala Ile Leu Pro Leu

510 515

520

tgc ttc gag aag tca aaa tgg gtc gtc gcc aca att ctc gcc gtc ctc 1632

Cys Phe Glu Lys Ser Lys Trp Val Val Ala Thr Ile Leu Ala Val Leu

525 530 535 540

aaa gtc ggt cgg gca ttc aca ctc atc gac ccg tgc gac ccc tcg gca 1680

Lys Val Gly Arg Ala Phe Thr Leu Ile Asp Pro Cys Asp Pro Ser Ala

545

550

555

agg atg gcc cag gtc tgt cag cag acc tcc gcc aca gtc gct ctc acc 1728

Arg Met Ala Gln Val Cys Gln Gln Thr Ser Ala Thr Val Ala Leu Thr

560 565 570

tcc aaa ctc cac aac acc tta cgt tcc gtc gtt tcc cgc tgc att 1776 Ser Lys Leu His Asn Thr Thr Leu Arg Ser Val Val Ser Arg Cys Ile 575 580

585

gtg gtc gac gac ctc ctt cgg tcc tta ccc cac gcc gat ggc cgc 1824

Val Val Asp Asp Leu Leu Arg Ser Leu Pro His Ala Asp Gly Arg

590 595 600

610

605

tta aag gcc acc gtg aag cca cag gac ttg gcc tat gtt att ttc aca 1872 Leu Lys Ala Thr Val Lys Pro Gln Asp Leu Ala Tyr Val Ile Phe Thr

615

620

tct ggc agc aca gga gag ccg aaa ggc atc atg atc gaa cat cgg ggg 1920 Ser Gly Ser Thr Gly Glu Pro Lys Gly Ile Met Ile Glu His Arg Gly

625 630 635

ttc gtg tcg tgt gct atg aaa ttt ggc ccc gcg ctc gga atg gat gag 1968

Phe Val Ser Cys Ala Met Lys Phe Gly Pro Ala Leu Gly Met Asp Glu

cac acg cgc gct ctt caa ttc gcc tca tat gcg ttt ggc gct tgt ctg 2016

His Thr Arg Ala Leu Gln Phe Ala Ser Tyr Ala Phe Gly Ala Cys Leu

gta gaa gtt gtg aca gct ctg atg cac ggc ggc tgc gtc tgc atc cct 2064 Val Glu Val Val Thr Ala Leu Met His Gly Gly Cys Val Cys Ile Pro

tcc gat gac gat cgc ttg aac aat gta ccg gag ttc atc aaa agg gcc 2112 Ser Asp Asp Asg Leu Asn Asn Val Pro Glu Phe Ile Lys Arg Ala

cag gtg aac tgg gtg ata ctc act ccg tcg tat atc ggg aca ttc cag 2160 Gln Val Asn Trp Val IIe Leu Thr Pro Ser Tyr IIe Gly Thr Phe Gln

705

710

715

ccg gaa gat gtc cct gga cta caa aca ctg gta ttg gtt gga gaa cct 2208
Pro Glu Asp Val Pro Gly Leu Gln Thr Leu Val Leu Val Gly Glu Pro

720

725

730

atc tca gcg tct att cgg gat acc tgg gcc tcc cag gtt cga ctc ctg 2256

735

740

745

aat gcc tac ggt cag agt gaa agc tca act atg tgc agc gtc acg gaa 2304 Asn Ala Tyr Gly Gln Ser Glu Ser Ser Thr Met Cys Ser Val Thr Glu gtc agc ccg ctc tcc ctc gaa ccg aac aat atc ggt cgg gct gta ggc 2352

Val Ser Pro Leu Ser Leu Glu Pro Asn Asn Ile Gly Arg Ala Val Gly

gca cga tcc tgg atc att gat ccc gac gag cct gat cgt ctt gct cca 2400 Ala Arg Ser Trp Ile Ile Asp Pro Asp Glu Pro Asp Arg Leu Ala Pro

att ggc tgc att gga gag cta gtg atc gaa agt ccg ggc att gcg cgc 2448

. 800

gac tat atc atc gcg ccg ccg ccg gac aag tcc ccc ttt ctc cta gca

Asp Tyr Ile Ile Ala Pro Pro Pro Asp Lys Ser Pro Phe Leu Leu Ala

815 820 825

ccc ccg gcc tgg tat cca gcc ggg aaa tta tcc aac gcc ttt aaa ttt 2544

Pro Pro Ala Trp Tyr Pro Ala Gly Lys Leu Ser Asn Ala Phe Lys Phe

830 835 840.

850

845

tac aag act gga gat ctc gtg cgt tat gga cct gac ggc acc atc gte 2592

Tyr Lys Thr Gly Asp Leu Val Arg Tyr Gly Pro Asp Gly Thr Ile Val

855

860

tgc ctg gga cgc aaa gat tcg caa gtg aag atc cga ggg cag cgc gta 2640 Cys Leu Gly Arg Lys Asp Ser Gln Val Lys Ile Arg Gly Gln Arg Val

865 870 875

gag atc agc gca gtg gaa gcc agt cta cga cga caa cta cct agt gac 2 Glu Ile Ser Ala Val Glu Ala Ser Leu Arg Arg Gln Leu Pro Ser Asp

880

885

890

atc atg ccc gtg gcc gaa gct atc aaa cgc tcg gat tcg tca ggc agc 2736
.
Ile Met Pro Val Ala Glu Ala Ile Lys Arg Ser Asp Ser Ser Gly Ser

895

900

905

aca gtc ttg act gcc ttc ttg ata ggg tca tct aag agc gga gat ggt 2784

Thr Val Leu Thr Ala Phe Leu Ile Gly Ser Ser Lys Ser Gly Asp Gly

910

915

920

aat ggc cac gct tta tct gcg gca gac gcc gtt atc ttg gat cac ggt 2832

Asn Gly His Ala Leu Ser Ala Ala Asp Ala Val Ile Leu Asp His Gly
925 930 935 940

gct acc aac gag ata aac gcg aag ttg cag caa atc ctt ccc cag cat 2880 Ala Thr Asn Glu Ile Asn Ala Lys Leu Gln Gln Ile Leu Pro Gln His

945 950 955

tcc gtt cca tcc tat tat atc cac atg gaa aat ctt cct cga act gcc 2928 Ser Val Pro Ser Tyr Tyr Ile His Met Glu Asn Leu Pro Arg Thr Ala

960 965 970

acc ggc aaa gcg gac agg aaa atg ctt cga tct att gct agc aag cta 2976

Thr Gly Lys Ala Asp Arg Lys Met Leu Arg Ser Ile Ala Ser Lys Leu

975 980 985

ttg ggt gaa ttg tct cag aac gtg aca tct caa ccg att gag aag cac 3024

Leu Gly Glu Leu Ser Gln Asn Val Thr Ser Gln Pro Ile Glu Lys His

990 995 1000

Asp Ala Pro Ala Thr Gly Ile Glu Val Lys Leu Lys Glu Leu Trp Phe

1005

1010

1020

ctg agc ttg aat ctt aat ccc aac tct caa gat gtc gga gcg agt ttc 3120

Leu Ser Leu Asn Leu Asn Pro Asn Ser Gln Asp Val Gly Ala Ser Phe

1025 1030 1035

ttt gac tta ggc gga aat tcc att atc gcc atc aaa atg gta aac atg 3168 Phe Asp Leu Gly Gly Asn Ser Ile Ile Ala Ile Lys Met Val Asn Met 1040

1045

1050

gcg agg tca gct ggg ata gca ctg aag gta tcc gac ata ttc cag aat 3216 Ala Arg Ser Ala Gly Ile Ala Leu Lys Val Ser Asp Ile Phe Gln Asn

1055

1060

1065

ccc acg ctc gcc ggc ctt gtg gat gtc atc ggg cga gac ccg gct ccg 3264
Pro Thr Leu Ala Gly Leu Val Asp Val Ile Gly Arg Asp Pro Ala Pro

1070

1075

1080

tac aac ctc atc cca aca aca gca tac agc gga cct gtt gag cag tcg 3312

Tyr Asn Leu Ile Pro Thr Thr Ala Tyr Ser Gly Pro Val Glu Gln Ser

1085 1090 1095 1100

ttc gcc cag ggc cgt cta tgg ttc ttg gac cag atc gaa ctc gat gcg 3360

Phe Ala Gln Gly Arg Leu Trp Phe Leu Asp Gln Ile Glu Leu Asp Ala

ttg tgg tac ctt cta cca tac gcc gtt cgc atg cgc ggg cca ttg cat 3408 Leu Trp Tyr Leu Leu Pro Tyr Ala Val Arg Met Arg Gly Pro Leu His

att gat gcg ctc act att gcg ttg cta gct ata cag caa cga cat gaa 3456 Ile Asp Ala Leu Thr Ile Ala Leu Leu Ala Ile Gln Gln Arg His Glu

acc ttg cgg aca acc ttt gag gag cag gac ggc gta ggc gtt cag gtt 3504

Thr Leu Arg Thr Thr Phe Glu Glu Gln Asp Gly Val Gly Val Gln Val

yal His Ala Ser Pro Ile Ser Asp Leu Arg Ile Ile Asp Val Ser Gly

1165 1170 1175 1180

gac cga aac agt gac tac ctc cag ttg cta cac caa gag cag acg act 3600
Asp Arg Asn Ser Asp Tyr Leu Gln Leu Leu His Gln Glu Gln Thr Thr

cca ttc att cta gca tgt cag gca gga tgg agg gta tca ctg att aga 3648

Pro Phe Ile Leu Ala Cys Gln Ala Gly Trp Arg Val Ser Leu Ile Arg

cta gga gaa gat gat cac atc ctc tct atc gta atg cat cac atc atc 3696 Leu Gly Glu Asp Asp His Ile Leu Ser Ile Val Met His His Ile Ile tcc gac ggc tgg tct atc gac att cta cgc cgg gaa cta agc aat ttc 3744

Ser Asp Gly Trp Ser Ile Asp Ile Leu Arg Arg Glu Leu Ser Asn Phe

tat tca gcc gct ctc cgg ggc tct gat cct cta tcg gtg gtg agc cca 37

Tyr Ser Ala Ala Leu Arg Gly Ser Asp Pro Leu Ser Val Val Ser Pro

ctc cca ctc cac tac cgc gac ttt tcc gtt tgg caa aag cag gtc gaa 38

Leu Pro Leu His Tyr Arg Asp Phe Ser Val Trp Gln Lys Gln Val Glu

cag gag acc gaa cat gag cgg caa ctc gaa tac tgg gtc aag cag ctc 3888 Gln Glu Thr Glu His Glu Arg Gln Leu Glu Tyr Trp Val Lys Gln Leu

1280 1285 1290

gca gac agc tcg gcc gcc gaa ttc cta acc gac ttc ccc cga ccc aac 3936 Ala Asp Ser Ser Ala Ala Glu Phe Leu Thr Asp Phe Pro Arg Pro Asn

1305

1300

1295

ata ctg tcc ggt gaa gca ggt tcc gtg cca gtg acg atc gaa ggc gaa 3984

Ile Leu Ser Gly Glu Ala Gly Ser Val Pro Val Thr Ile Glu Gly Glu

1310 1315 1320

Leu Tyr Glu Arg Leu Gln Glu Phe Cys Lys Val Glu Gln Met Thr Pro

1325

1330

1340

ttc gcc gtg ttg tta ggg gcc ttc cgc gcg acc cat tat cgt ctc acc 4080 Phe Ala Val Leu Gly Ala Phe Arg Ala Thr His Tyr Arg Leu Thr

1345

1350

1355

ggc gcc gaa gac tcg atc atc ggc acg ccc atc gcg aac cgc aac cgc 4128

Gly Ala Glu Asp Ser Ile Ile Gly Thr Pro Ile Ala Asn Arg Asn Arg

1360

1365

1370

Cag gag ctt gaa aac atg atc ggc ttc ttc gtc aac acc caa tgc atg 4176 Gln Glu Leu Glu Asn Met Ile Gly Phe Phe Val Asn Thr Gln Cys Met

1375

1380

1385

cga atc acg gtc gac ggc gac act ttt gaa agc ctg gtg cga caa 4224

Arg Ile Thr Val Asp Gly Asp Asp Thr Phe Glu Ser Leu Val Arg Gln

1390 1395 1400

1425

gtt cgg acc acg gcg acg gcg gca ttc gag cac caa gac gtc ccc ttt 4272

Val Arg Thr Thr Ala Thr Ala Ala Phe Glu His Gln Asp Val Pro Phe

1405 1410 1415 1420

gag cgc gtc gtg acg gca ctc ctt cca cgc tcg aga gac cta tcc cga 4320 Glu Arg Val Val Thr Ala Leu Leu Pro Arg Ser Arg Asp Leu Ser Arg

1430

1435

aac cca cta gca cag ctc acc ttc gct ctt cat tct caa cag gac ctc 4368
Asn Pro Leu Ala Gln Leu Thr Phe Ala Leu His Ser Gln Gln Asp Leu

1440 . 1445 1450

ggc aag ttc gag ctg gag ggt ctc gta gcg gaa ccc gtc tcg aac aag 4416 Gly Lys Phe Glu Leu Glu Gly Leu Val Ala Glu Pro Val Ser Asn Lys

1455

1460

1465

gta tac acc agg ttc gac gtg gag ttt cac ctg ttc caa gaa gcc gga 4464

Val Tyr Thr Arg Phe Asp Val Glu Phe His Leu Phe Gln Glu Ala Gly

1470 1475 1480

Arg Leu Ser Gly Asn Val Ala Phe Ala Ala Asp Leu Phe Lys Pro Glu

1485

1490

1495

1500

acc att agc aat gta gtc gcc ata ttt ttc caa atc ctg cga caa ggc 4560 Thr Ile Ser Asn Val Val Ala Ile Phe Phe Gln Ile Leu Arg Gln Gly att cgc cag cct cgg act cca atc gct gtt ctc ccg ctt acc gat ggg 4608 !!
Ile Arg Gln Pro Arg Thr Pro Ile Ala Val Leu Pro Leu Thr Asp Gly

tta gcg gac ctt cgt gcc atg ggc ttg ctt gag atc gag aag gca gaa 4656 Leu Ala Asp Leu Arg Ala Met Gly Leu Leu Glu Ile Glu Lys Ala Glu

tac ccg cgg gag tcg agc gtc gtc gac gtc ttc cgc aag cag gtg gcc 4704

Tyr Pro Arg Glu Ser Ser Val Val Asp Val Phe Arg Lys Gln Val Ala

get cae eeg cae get tit gee git gie gat teg gea teg ege ete aca 4752

Ala His Pro His Ala Phe Ala Val Val Asp Ser Ala Ser Arg Leu Thr 1565 1570 1575 1580

tat gct gat ctc gat cgt caa tcc gat caa ctc gcg acc tgg ctc ggt 4800

Tyr Ala Asp Leu Asp Arg Gln Ser Asp Gln Leu Ala Thr Trp Leu Gly

1590

1595

1585

cgg cgc aat atg acg gct gag acg ctg gtc ggg gtg tta gca ccg cgg 4848

Arg Arg Asn Met Thr Ala Glu Thr Leu Val Gly Val Leu Ala Pro Arg

tca tgt caa aca gtt gtt gcc att tta ggt atc ctg aaa gcg aat ctc 4896 Ser Cys Gln Thr Val Val Ala IIe Leu Gly IIe Leu Lys Ala Asn Leu

1615 1620 1625

Ala Tyr Leu Pro Leu Asp Val Asn Cys Pro Thr Ala Arg Leu Gln Thr

1630 1635 1640

atc cta tct aca ttg aat cgg cac aag ttg gtc cta ctc ggc tct aac 4992

Ile Leu Ser Thr Leu Asn Arg His Lys Leu Val Leu Leu Gly Ser Asn

1645 1650 1655 1660

Ala Thr Thr Pro Asp Val Gln Ile Pro Asp Val Glu Leu Val Arg Ile

1665 1670 1675

agc gat atc tta gat cgc ccc atc aat ggc cag gca aag cta aat ggt 5088 Ser Asp Ile Leu Asp Arg Pro Ile Asn Gly Gln Ala Lys Leu Asn Gly cat aca aaa tcg aat ggc tac tca aag cca aac ggc tat acg cat ctg His Thr Lys Ser Asn Gly Tyr Ser Lys Pro Asn Gly Tyr Thr His Leu

1695 . . .

aaa ggc tat tca aac cta aac ggt tat tca aaa caa aat ggt tat gca Lys Gly Tyr Ser Asn Leu Asn Gly Tyr Ser Lys Gln Asn Gly Tyr Ala

caa ctc aac ggc cat aga gag cgt aac aat tat tta gat cta aat ggg Gln Leu Asn Gly His Arg Glu Arg Asn Asn Tyr Leu Asp Leu Asn Gly

cac tca ctg cta aat ggg aat tca gac atc acc aca tca ggg ccc tca 5280 His Ser Leu Leu Asn Gly Asn Ser Asp Ile Thr Thr Ser Gly Pro Ser

1745 1750 1755

gca aca agc ctt gcc tac gtg atc ttc aca tcc ggc tca acc gga aag 5328
Ala Thr Ser Leu Ala Tyr Val Ile Phe Thr Ser Gly Ser Thr Gly Lys

. 1770

1765

ccc aaa gga gtc atg gtc gaa cac cgc agc atc atc cga ctt gca aag 5376
Pro Lys Gly Val Met Val Glu His Arg Ser Ile Ile Arg Leu Ala Lys

1775 1780 1785

1760

aag aac aga atc ata tcc agg ttc cca tct gta gcc aag gta gct cac 5424 Lys Asn Arg Ile Ile Ser Arg Phe Pro Ser Val Ala Lys Val Ala His

1790 1795 1800

ctc tca aac atc gcc ttt gac gcc gcc act tgg gaa atg ttc gca gcc 5472

Leu Ser Asn Ile Ala Phe Asp Ala Ala Thr Trp Glu Met Phe Ala Ala

1805 1810 1815 1820

ctt cta aac ggc gga acg ctg gtc tgt atc gac tat atg acc acc ctg 5520 Leu Leu Asn Gly Gly Thr Leu Val Cys Ile Asp Tyr Met Thr Thr Leu 1825 1830 1835

Asp Ser Lys Thr Leu Glu Ala Ala Phe Ala Arg Glu Gln Ile Asn Ala

gcg tta ctc acg ccc gct ttg ttg aag cag tgc cta gcc aac att ccc 5616

Ala Leu Leu Thr Pro Ala Leu Leu Lys Gln Cys Leu Ala Asn Ile Pro

act acc cta ggc agg ctg agt gca ctc gtt att gga ggt gat agg ctt

Thr Thr Leu Gly Arg Leu Ser Ala Leu Val Ile Gly Gly Asp Arg Leu

gac ggc caa gac gcg atc gca gca cat gcg ctt gtc ggt gct ggc gtg Asp Gly Gln Asp Ala Ile Ala Ala His Ala Leu Val Gly Ala Gly Val

tat aat gcg tat ggc ccg acc gaa aac gga gtg atc agt acg att tat Tyr Asn Ala Tyr Gly Pro Thr Glu Asn Gly Val Ile Ser Thr Ile Tyr

aat atc act aaa aac gac tcg ttc atc aac gga gtc ccc atc ggc tgt 5808 Asn Ile Thr Lys Asn Asp Ser Phe Ile Asn Gly Val Pro Ile Gly Cys

1920

1935

1950

1925

1930

1945

1960

gca atc agc aat tcc ggc gcc tac atc aca gac cca gac cag cag ctc 5856

Ala Ile Ser Asn Ser Gly Ala Tyr Ile Thr Asp Pro Asp Gln Gln Leu

1940

1955

gta cct cct ggc gtc atg ggt gaa ctc gtc gtt acc ggt gac ggg ctc 5904
Val Pro Pro Gly Val Met Gly Glu Leu Val Val Thr Gly Asp Gly Leu

gcg cgg ggg tat aca gac cca gca cta gac gcg ggc cgc ttc gtc cag 5952 Ala Arg Gly Tyr Thr Asp Pro Ala Leu Asp Ala Gly Arg Phe Val Gln atc atg atc aat gac aag gcc gtg agg gcg tac cga acg ggt gac cgg 6000

Ile Met Ile Asn Asp Lys Ala Val Arg Ala Tyr Arg Thr Gly Asp Arg

gca cga tat cgc gta gga gac ggt cag atc gag ttc ttc gga cgc atg 6048 Ala Arg Tyr Arg Val Gly Asp Gly Gln Ile Glu Phe Phe Gly Arg Met

gat cag caa gtc aag atc cga ggt cac cgc att gaa cca gcc gaa gtg 6096 Asp Gln Gln Val Lys Ile Arg Gly His Arg Ile Glu Pro Ala Glu Val

gag cgt gct att ctc gac caa gac tcg gcc cgc gac gcc gtc gtt gtc 6144

Glu Arg Ala Ile Leu Asp Gln Asp Ser Ala Arg Asp Ala Val Val

2030

2035

2040

atc cgg cac caa gaa ggt gaa gaa ccg gag atg gtt ggt ttc gtc gcg 6192

Ile Arg His Gln Glu Gly Glu Glu Pro Glu Met Val Gly Phe Val Ala

2045 2050 2055 2060

acc cac ggc gat cac tct gcc gaa caa gag gaa gca gac gac cag gtt 6240

Thr His Gly Asp His Ser Ala Glu Gln Glu Glu Ala Asp Asp Gln Val

2065

2070

2075

gaa ggt tgg aaa gac ttc ttc gag agc aat aca tat gcc gac atg gat 6288 Glu Gly Trp Lys Asp Phe Phe Glu Ser Asn Thr Tyr Ala Asp Met Asp

2080

2085

acc atc ggc cag tct gct ata ggc aac gac ttt acg ggc tgg acg tcc 6336 Thr Ile Gly Gln Ser Æla Ile Gly Asn Asp Phe Thr Gly Trp Thr Ser

2095

2100

2105

atg tac gac ggg agc gag atc aac aag gcc gag atg cag gag tgg ctc 6384

Met Tyr Asp Gly Ser Glu Ile Asn Lys Ala Glu Met Gln Glu Trp Leu

2110 2115 2120

Asp Asp Thr Met Arg Thr Leu Leu Asp Gly Gln Ala Pro Gly His Val

2125
2130
2135
2140

ctc gaa ata ggc aca ggc agt ggc atg gta ttg ttt aac tta ggg gcc 6480 Leu Glu Ile Gly Thr Gly Ser Gly Met Val Leu Phe Asn Leu Gly Ala ggg cta caa agc tac gta ggt ctt gaa cca tct aga tct gca gcc acg 6528 Gly Leu Gln Ser Tyr Val Gly Leu Glu Pro Ser Arg Ser Ala Ala Thr

ttt gtt acc aaa gcg atc aat tcc acc cca gct ctt gca gga aag gcc 6576 Phe Val Thr Lys Ala Ile Asn Ser Thr Pro Ala Leu Ala Gly Lys Ala

gaa gtg cac gtc ggc aca gcg aca gac ata aac cga ctt cgt gga ctt 6624 Glu Val His Val Gly Thr Ala Thr Asp Ile Asn Arg Leu Arg Gly Leu

Arg Pro Asp Leu Val Val Leu Asn Ser Val Val Gln Tyr Phe Pro Thr

2205 2210 2215 2220

ccc gag tac cta cta gag gtc gtg gag agt ctc gtc cgg att ccg ggc 6720 Pro Glu Tyr Leu Leu Glu Val Val Glu Ser Leu Val Arg Ile Pro Gly

2225 2230 2235

gtc aag cgc gtg gtc ttc ggc gac ata cga tct cac gcc acg aac aga 6768 Val Lys Arg Val Val Phe Gly Asp Ile Arg Ser His Ala Thr Asn Arg

2240 2245 2250

cat tit cit gct gcc agg gcg cig cat tcg cig ggc tcc aag gcg acc 6816 His Phe Leu Ala Ala Arg Ala Leu His Ser Leu Gly Ser Lys Ala Thr

2255.

2260

aaa gat gct ata cgt caa aag atg acg gag atg gaa gag cgc gag gaa 6864

Lys Asp Ala Ile Arg Gln Lys Met Thr Glu Met Glu Glu Arg Glu Glu

2270

2275

2280

Glu Leu Leu Val Asp Pro Ala Phe Phe Thr Ala Leu Leu Gln Gly Gln

2285
2290
2295
2300

ctt gcc gat cga atc aag cac gtc gag atc ctc ccg aag aac atg cgc 6960 Leu Ala Asp Arg Ile Lys His Val Glu Ile Leu Pro Lys Asn Met Arg

gcc acg aac gag ctg agc gcg tac cgg tat aca gcc gtc att cac gta 7008

Ala Thr Asn Glu Leu Ser Ala Tyr Arg Tyr Thr Ala Val Ile His Val

cgc ggc cca gag gaa cag tcg cgg ccc gtg tat ccg atc caa gtg aac

Arg Gly Pro Glu Glu Gln Ser Arg Pro Val Tyr Pro Ile Gln Val Asn

gac tgg atc gac ttt cag gcc tca cgc att gac cgc cgc gcc ctt ctc

Asp Trp Ile Asp Phe Gln Ala Ser Arg Ile Asp Arg Ala Leu Leu

cga ctc cta cag cgc tcg gca gac gcc gcg acc gtc gcc gtc agc aac

Arg Leu Leu Gln Arg Ser Ala Asp Ala Ala Thr Val Ala Val Ser Asn

atc ccc tac agc aag acg att gta gaa cgc cat gtc gtc gag tcc ctt 7200

Ile Pro Tyr Ser Lys Thr Ile Val Glu Arg His Val Val Glu Ser Leu

2385

2390

2395

gac aat aac aag gag aat acg cat aga gca cca gac ggc gcg gct 7248
Asp Asn Asn Asn Arg Glu Asn Thr His Arg Ala Pro Asp Gly Ala Ala

2400

2405

2410

tgg atc tcg gcc gtc cgc tcc aag gcc gag cgc tgc acg tcc ctc tcc 7296

Trp Ile Ser Ala Val Arg Ser Lys Ala Glu Arg Cys Thr Ser Leu Ser

2415

2420

2425

gtg acc gat ctt gtg cag ctc ggg gaa gaa gcc ggc ttt cgc gta gaa 7344 Val Thr Asp Leu Val Gln Leu Gly Glu Glu Ala Gly Phe Arg Val Glu gtc agc gca gcg cgg cag tgg tct caa agc ggc gcg ctc gat gcc gtc 7392

Val Ser Ala Ala Arg Gln Trp Ser Gln Ser Gly Ala Leu Asp Ala Val

2445 2450 2455 2460

ttt cac cgc tat aat ttg ccc act caa agc aat agt cgc gtt ctg att 7440

Phe His Arg Tyr Asn Leu Pro Thr Gln Ser Asn Ser Arg Val Leu Ile

2465 2470 2475

Cag ttc cct acc gaa gat ggc cag acg cga aga tcc gcc act ctg aca 7488

Gln Phe Pro Thr Glu Asp Gly Gln Thr Arg Arg Ser Ala Thr Leu Thr

2480 2485 2490

aac cga cca cta cag cgt ctg cag agc cgt cgg ttc gca tca cag atc 7536

Asn Arg Pro Leu Gln Arg Leu Gln Ser Arg Arg Phe Ala Ser Gln Ile

2495

2500

2505

cgc gaa cag ctg aag gcc gtg ctc ccg tca tac atg atc ccc tcc cgc 7584

Arg Glu Gln Leu Lys Ala Val Leu Pro Ser Tyr Met Ile Pro Ser Arg

2510 2515 2520

atc gtg gtc ata gac cag atg cct ctc aat gcc aat ggc aag gtc gac 7632

Ile Val Val Ile Asp Gln Met Pro Leu Asn Ala Asn Gly Lys Val Asp

2525 2530 2535 2540

Cgg aaa gaa ctt acc aga agg gcc caa atc gcg ccg aaa tct cag gcg 7680 Arg Lys Glu Leu Thr Arg Arg Ala Gln Ile Ala Pro Lys Ser Gln Ala

2545

2550

gct ccc gcc aaa ccc gtc aaa cag gtc gat ccg ttc gtc aac ctg gaa 7728 Ala Pro Ala Lys Pro Val Lys Gln Val Asp Pro Phe Val Asn Leu Glu

2560 2565 2570

gcc att tta tgt gag gag ttc gcg gag gtg ctg ggc atg gaa gtc ggc 7776
Ala Ile Leu Cys Glu Glu Phe Ala Glu Val Leu Gly Met Glu Val Gly

2575 2580 2585

2595

2590

gtg aac gac cac ttc ttc caa cta ggc gga cac tct ctc ttg gcc acg 7824

Val Asn Asp His Phe Phe Gln Leu Gly Gly His Ser Leu Leu Ala Thr

2600

aag ctc gtc gcg cgt ctc agt cgt cgg cta aac ggt cgt gtg tct gtg 7872 Lys Leu Val Ala Arg Leu Ser Arg Arg Leu Asn Gly Arg Val Ser Val

agg gat gtg ttc gac cag cct gtg att tcc gac ctc gca gtc acc ctc 7920

Arg Asp Val Phe Asp Gln Pro Val Ile Ser Asp Leu Ala Val Thr Leu

cgc cag gga ctg acc ttg gaa aac gcc att ccc gca acg ccg gac agc 7968

Arg Gln Gly Leu Thr Leu Glu Asn Ala Ile Pro Ala Thr Pro Asp Ser

ggg tat tgg gag cag aca atg tcc gca ccg aca acc ccg agc gac gac 8016

Gly Tyr Trp Glu Gln Thr Met Ser Ala Pro Thr Thr Pro Ser Asp Asp

atg gag gcc gtg cta tgc aag gag ttt gcg gat gtg ctt ggc gtc gaa 8064 Met Glu Ala Val Leu Cys Lys Glu Phe Ala Asp Val Leu Gly Val Glu

2670 2675 2680

yal Ser Ala Thr Asp Ser Phe Phe Asp Leu Gly Gly His Ser Leu Met

2685

2690

2695

2700

gct acg aag ctc gct gcg cgt att agc cgt cgg cta gat gta ccg gtg 8160 Ala Thr Lys Leu Ala Ala Arg Ile Ser Arg Arg Leu Asp Val Pro Val

2705 2710 2715

tca atc aaa gac ata ttc gat cac tca gtt cct cta aac ctt gcg agg 8208 Ser Ile Lys Asp Ile Phe Asp His Ser Val Pro Leu Asn Leu Ala Arg

2720 2725 2730

aag att cgg ctc act caa gca aaa ggc cac gaa gcg acc aat gga gta 8256 Lys Ile Arg Leu Thr Gln Ala Lys Gly His Glu Ala Thr Asn Gly Val

2735

2740

2745

Caa atc gcc aac gcc cca ttc caa ctc att tcc gta gaa gat cca 8304 Gln Ile Ala Asn Asp Ala Pro Phe Gln Leu Ile Ser Val Glu Asp Pro 2750 2755 2760

Glu Ile Phe Val Gln Arg Glu Ile Ala Pro Gln Leu Gln Cys Ser Pro

2765
2770
2775
2780

gag aca atc cta gac gtc tac ccc gcc acg caa atg caa agg gtc ttc 8400

Glu Thr Ile Leu Asp Val Tyr Pro Ala Thr Gln Met Gln Arg Val Phe

ctc ctc aac cca gta aca gga aag ccg cgc tca cca acg cca ttt cac 8448

Leu Leu Asn Pro Val Thr Gly Lys Pro Arg Ser Pro Thr Pro Phe His

ata gac ttc ccg ccg gac gca gac tgc gcc agc ctg atg cgg gca tgt 8496

Ile Asp Phe Pro Pro Asp Ala Asp Cys Ala Ser Leu Met Arg Ala Cys

gca tct cta gcg aag cat ttc gat atc ttc agg acg gtg ttc ctc gaa 8544 Ala Ser Leu Ala Lys His Phe Asp Ile Phe Arg Thr Val Phe Leu Glu

Ala Arg Gly Glu Leu Tyr Gln Val Val Leu Lys His Val Asp Val Pro

2845
2850
2855
2860

atc gag atg ctc cag acc gaa gaa aac atc aac agc gcg acc cgg tcg 8640

Ile Glu Met Leu Gln Thr Glu Glu Asn Ile Asn Ser Ala Thr Arg Ser

2865 2870 2875

ttc ctg gac gta gac gca gaa aaa ccc atc cgg cta ggc cag cca ctg 8688

Phe Leu Asp Val Asp Ala Glu Lys Pro Ile Arg Leu Gly Gln Pro Leu

2880 2885 2890

atc cgc atc gcg ata cta gag aag ccc ggg tcc acg ctg cgc gtc atc 8736

Ile Arg Ile Ala Ile Leu Glu Lys Pro Gly Ser Thr Leu Arg Val Ile

cta cga tta tcc cac gcc tta tac gac ggc ctg agc cta gag cac atc

Leu Arg Leu Ser His Ala Leu Tyr Asp Gly Leu Ser Leu Glu His Ile

ctg cac tct ctg cac atc ctc ttt ttc ggc ggc agt ctt ccc ccg ccg

Leu His Ser Leu His Ile Leu Phe Phe Gly Gly Ser Leu Pro Pro

ccc aag ttc gcc ggg tac atg caa cac gtc gcg agc agt cgc aga gaa

Pro Lys Phe Ala Gly Tyr Met Gln His Val Ala Ser Ser Arg Arg Glu

ggc tac gat ttc tgg cgt tcc gtt ctc cga gat tcg tct atg aca gtc

Gly Tyr Asp Phe Trp Arg Ser Val Leu Arg Asp Ser Ser Met Thr Val

Ile Lys Gly Asn Asn Asn Thr Thr Pro Pro Pro Pro Gln Gln Gln

tcc acc ccc tcc gga gcc cac cac gcc tcc aaa gta gtc act atc cca 9024

Ser Thr Pro Ser Gly Ala His His Ala Ser Lys Val Val Thr Ile Pro

acc caa gcc aac aca gac agc cgg atc acg cgc gcc acg atc ttc act 907

Thr Gln Ala Asn Thr Asp Ser Arg Ile Thr Arg Ala Thr Ile Phe Thr

acc gct tgc gca cta atg ctc gcg aaa gaa gac aac tcc agc gac gtc 9120
Thr Ala Cys Ala Leu Met Leu Ala Lys Glu Asp Asn Ser Ser Asp Val

3025 3030 3035

gtc ttc ggg cgt acg gta tcg ggg cgt caa ggc ctg ccc cta gcc cac 9168
Val Phe Gly Arg Thr Val Ser Gly Arg Gln Gly Leu Pro Leu Ala His

3040 3045 3050

Caa aac gtg atc gga cca tgt ctc aac caa gtg ccc gtg cgc gcg cgc 9216 Gln Asn Val Ile Gly Pro Cys Leu Asn Gln Val Pro Val Arg Ala Arg

3055 3060 3065

ggt tta aac cga gga acc act cac cgc cga gaa ctt ctc cgc gag atg 9264

Gly Leu Asn Arg Gly Thr Thr His His Arg Glu Leu Leu Arg Glu Met

caa gag caa tat ctc aac agt ctc gct ttc gaa act ctc ggg tac gac Gln Glu Gln Tyr Leu Asn Ser Leu Ala Phe Glu Thr Leu Gly Tyr Asp . 3090

gag atc aag gcg cac tgc aca gac tgg ccg gac gtg cca gcg acc gcg Glu Ile Lys Ala His Cys Thr Asp Trp Pro Asp Val Pro Ala Thr Ala

age tte ggg tge tge ate gtg tae cag aac tte gat teg cae eeg gae Ser Phe Gly Cys Cys Ile Val Tyr Gln Asn Phe Asp Ser His Pro Asp

agc cga gtc gaa gag cag cgg ctg cag atc ggg gtc ttg tcg cgg aac 9456 Ser Arg Val Glu Glu Gln Arg Leu Gln Ile Gly Val Leu Ser Arg Asn

3140

3135

3145

tac gag gct att aat gag ggg ctc gtg cat gat ctt gtt att gct ggg 9504

Tyr Glu Ala Ile Asn Glu Gly Leu Val His Asp Leu Val Ile Ala Gly

3150 3155 3160.

gag tcg gag cct gat ggg gat gat ttg agg gtt act gtt gtg gcg aat 9552

Glu Ser Glu Pro Asp Gly Asp Asp Leu Arg Val Thr Val Val Ala Asn

3165 3170 3175 3180

cgg agg ttg tgc gat gag gaa agg ttg aag agg atg ctg gag gag ctg 9600 Arg Arg Leu Cys Asp Glu Glu Arg Leu Lys Arg Met Leu Glu Glu Leu

3185 . 3190 3195

tgt ggg aat att cgg gct ttg gcg ttg gtt tag

9633

Cys Gly Asn Ile Arg Ala Leu Ala Leu Val

3200

3205

<210> 2

<211> 3210

<212> PRT

<213> Mycelia sterilia

<400> 2

Met Ser Asn Met Ala Pro Leu Pro Thr Met Gly Val Glu Gln Gln Ala

1

5 .

10

Leu Ser Leu Ser Cys Pro Leu Leu Pro His Asp Asp Glu Lys His Ser

Asp Asn Leu Tyr Glu Gln Ala Thr Arg His Phe Gly Leu Ser Arg Asp

Lys Ile Glu Asn Val Leu Pro Cys Thr Ser Phe Gln Cys Asp Val Ile

Asp Cys Ala Val Asp Asp Arg Arg His Ala Ile Gly His Val Val Tyr

Asp Ile Pro Asn Thr Val Asp Ile Gln Arg Leu Ala Ala Arp Lys

Glu Val Val Arg Gln Thr Pro Ile Leu Arg Thr Gly Ile Phe Thr Ser

Glu Thr Gly Asp Ser Phe Gln IIe Val Leu Lys Glu Gly Cys Leu Pro

Trp Met Tyr Ala Thr Cys Leu Gly Met Lys Gly Ala Val Ile Gln Asp

Glu Ala Val Ala Ala Met Thr Gly Pro Arg Cys Asn Arg Tyr Val Val

Leu Glu Asp Pro Ser Thr Lys Gln Arg Leu Leu Ile Trp Thr Phe Ser

His Ala Leu Val Asp Tyr Thr Val Gln Glu Arg Ile Leu Gln Arg Val

Leu Thr Val Tyr Asp Gly Arg Asp Val Glu Cys Pro Arg Ile Lys Asp

Thr Glu His Val Ser Arg Phe Trp Gln Gln His Phe Glu Gly Leu Asp

Ala Ser Val Phe Pro Leu Leu Pro Ser His Leu Thr Val Cys Asn Pro

Asn Ala Arg Ala Glu His His Ile Ser Tyr Thr Gly Pro Val Gln Arg

Lys Trp Ser His Thr Ser Ile Cys Arg Ala Ala Leu Ala Val Leu Leu

Ser Arg Phe Thr His Ser Ser Glu Ala Leu Phe Gly Val Val Thr Glu

Gln Ser His Asn Ser Glu Asp Gln Arg Arg Ser Ile Asp Gly Pro Ala

Arg Thr Val Val Pro Ile Arg Val Leu Cys Ala Pro Asp Gln Tyr Val

Ser Asp Val Ile Gly Ala Ile Thr Ala His Glu His Ala Met Arg Gly

Phe Glu His Ala Gly Leu Arg Asn Ile Arg Arg Thr Gly Asp Asp Gly

Ser Ala Ala Cys Gly Phe Gln Thr Val Leu Leu Val Thr Asp Gly Asp

Ala Pro Lys Thr Pro Gly Ser Val Leu His Arg Ser Val Glu Glu Ser

Asp Arg Phe Met Pro Cys Ala Asn Arg Ala Leu Leu Leu Asp Cys Gln

Met Ala Gly Asn Ser Ala Ser Leu Val Ala Arg Tyr Asp His Asn Val

Ile Asp Pro Arg Gln Met Ser Arg Phe Leu Arg Gln Leu Gly Tyr Leu

Ile Gln Gln Phe His His Val Asp Leu Pro Leu Val Lys Glu Leu

Asp Val Val Thr Ala Glu Asp Cys Ala Glu Ile Glu Lys Trp Asn Ser

Glu Arg Leu Thr Met Gln Asp Ala Leu Ile His Asp Thr Ile Ser Lys

Trp Ala Ala Gly Asp Pro Asn Lys Ala Ala Val Phe Ala Trp Asp Gly
485 490 495

Glu Trp Thr Tyr Ala Glu Leu Asp Asn Ile Ser Ser Arg Leu Ala Val

505

510

500

Tyr Ile Gln Ser Leu Asp Leu Arg Pro Gly Gln Ala Ile Leu Pro Leu
515 520 525

Cys Phe Glu Lys Ser Lys Trp Val Val Ala Thr Ile Leu Ala Val Leu
530 535 540

Lys Val Gly Arg Ala Phe Thr Leu Ile Asp Pro Cys Asp Pro Ser Ala
545 550 555 560

Arg Met Ala Gln Val Cys Gln Gln Thr Ser Ala Thr Val Ala Leu Thr

Ser Lys Leu His Asn Thr Thr Leu Arg Ser Val Val Ser Arg Cys Ile

Val Val Asp Asp Leu Leu Arg Ser Leu Pro His Ala Asp Gly Arg

Leu Lys Ala Thr Val Lys Pro Gln Asp Leu Ala Tyr Val Ile Phe Thr

Ser Gly Ser Thr Gly Glu Pro Lys Gly Ile Met Ile Glu His Arg Gly

Phe Val Ser Cys Ala Met Lys Phe Gly Pro Ala Leu Gly Met Asp Glu

His Thr Arg Ala Leu Gln Phe Ala Ser Tyr Ala Phe Gly Ala Cys Leu

Val Glu Val Val Thr Ala Leu Met His Gly Gly Cys Val Cys Ile Pro

Ser Asp Asp Asp Arg Leu Asn Asn Val Pro Glu Phe Ile Lys Arg Ala

Gln Val Asn Trp Val Ile Leu Thr Pro Ser Tyr Ile Gly Thr Phe Gln

Pro Glu Asp Val Pro Gly Leu Gln Thr Leu Val Leu Val Gly Glu Pro

Ile Ser Ala Ser Ile Arg Asp Thr Trp Ala Ser Gln Val Arg Leu Leu

Asn Ala Tyr Gly Gln Ser Glu Ser Ser Thr Met Cys Ser Val Thr Glu

Val Ser Pro Leu Ser Leu Glu Pro Asn Asn Ile Gly Arg Ala Val Gly

Ala	Arg	Ser	Trp	Ile	Ile	Asp	Pro	Asp	Glu	Pro	Asp	Arg	Leu	Ala	Pro
785					790					795					800
												-			
He	Gly	Cys	Ile	Gly	Glu	Leu	Val	Ile	Glu	Ser	Pro	Gly	Ile	Ala	Arg
			٠	805					810				٠	815	
													·		
Asp	Tyr	Ile	Ile	Ala	Pro	Pro	Pro	Asp	Lys	Ser	Pro	Phe	Leu	Leu	Ala
			820					825				:···.	830		
				-					•						
Pro	Pro	Ala	Trp	Tyr	Pro	Ala	Gly	Lys	Leu	Ser	Asn	Ala	Phe	Lys	Phe
	٠	835					840					845			
					٠										

Tyr Lys Thr Gly Asp Leu Val Arg Tyr Gly Pro Asp Gly Thr Ile Val

855 860

850

- 90 -

Cys Leu Gly Arg Lys Asp Ser Gln Val Lys Ile Arg Gly Gln Arg Val

865 870 875 880

Glu Ile Ser Ala Val Glu Ala Ser Leu Arg Arg Gln Leu Pro Ser Asp

885 890 895

Ile Met Pro Val Ala Glu Ala Ile Lys Arg Ser Asp Ser Ser Gly Ser

900 905 910

Thr Val Leu Thr Ala Phe Leu Ile Gly Ser Ser Lys Ser Gly Asp Gly

915 920 925

Asn Gly His Ala Leu Ser Ala Ala Asp Ala Val Ile Leu Asp His Gly

930 935 940

Ala Thr Asn Glu Ile Asn Ala Lys Leu Gln Gln Ile Leu Pro Gln His
945 950 955 960

Ser Val Pro Ser Tyr Tyr Ile His Met Glu Asn Leu Pro Arg Thr Ala 965 970 975

Thr Gly Lys Ala Asp Arg Lys Met Leu Arg Ser Ile Ala Ser Lys Leu
980 985 990

Leu Gly Glu Leu Ser Gln Asn Val Thr Ser Gln Pro Ile Glu Lys His
995 1000 1005

Asp Ala Pro Ala Thr Gly Ile Glu Val Lys Leu Lys Glu Leu Trp Phe

Leu Ser Leu Asn Leu Asn Pro Asn Ser Gln Asp Val Gly Ala Ser Phe

Phe Asp Leu Gly Gly Asn Ser Ile Ile Ala Ile Lys Met Val Asn Met

Ala Arg Ser Ala Gly Ile Ala Leu Lys Val Ser Asp Ile Phe Gln Asn

Pro Thr Leu Ala Gly Leu Val Asp Val Ile Gly Arg Asp Pro Ala Pro

Tyr Asn Leu Ile Pro Thr Thr Ala Tyr Ser Gly Pro Val Glu Gln Ser

Phe Ala Gln Gly Arg Leu Trp Phe Leu Asp Gln Ile Glu Leu Asp Ala

Leu Trp Tyr Leu Leu Pro Tyr Ala Val Arg Met Arg Gly Pro Leu His

Ile Asp Ala Leu Thr Ile Ala Leu Leu Ala Ile Gln Gln Arg His Glu

Thr Leu Arg Thr Thr Phe Glu Glu Gln Asp Gly Val Gly Val Gln Val

Val His	Ala Ser Pro	Ile Ser Asp	Leu Arg Ile II	e Asp Val Ser Gly
1170		1175		0
Asp Arg	Asn Ser Asp	Tyr Leu Gln	Leu Leu His Gl	n Glu Gln Thr Thr
185	•	1190	1195	1200
	•			
Pro Phe	Ile Leu Ala	Cys Gln Ala	Gly Trp Arg Val	l Ser Leu Ile Arg
	1205		1210	1215
		•		
Leu Gly	Glu Asp Asp	His Ile Leu	Ser Ile Val Met	His His Ile Ile
	1220	. 1	225	1230
	,	•		-
Ser Asp	Gly Trp Ser	Ile Asp Ile	Leu Arg Arg Glu	Leu Ser Asn Phe
. 1	235	1240		1245

Tyr S	Ser	Ala	Ala	Leu	Arg	Gly	Ser	Asp	Pro	Leu	Ser	Val	Val	Ser	Pro
12	250				1	255				1	260				

Leu Pro Leu His Tyr Arg Asp Phe Ser Val Trp Gln Lys Gln Val Glu 265 1270 1275 1280

Gln Glu Thr Glu His Glu Arg Gln Leu Glu Tyr Trp Val Lys Gln Leu
1285 1290 1295

Ala Asp Ser Ser Ala Ala Glu Phe Leu Thr Asp Phe Pro Arg Pro Asn 1300 1305 1310

Ile Leu Ser Gly Glu Ala Gly Ser Val Pro Val Thr Ile Glu Gly Glu

1315 1320 1325

Leu Tyr Glu Arg Leu Gln Glu Phe Cys Lys Val Glu Gln Met Thr Pro 1330 1335 1340

Phe Ala Val Leu Leu Gly Ala Phe Arg Ala Thr His Tyr Arg Leu Thr

1350 1355 1360

Gly Ala Glu Asp Ser Ile Ile Gly Thr Pro Ile Ala Asn Arg Asn Arg
1365 1370 1375

Gln Glu Leu Glu Asn Met Ile Gly Phe Phe Val Asn Thr Gln Cys Met 1380 1385 1390

Arg Ile Thr Val Asp Gly Asp Asp Thr Phe Glu Ser Leu Val Arg Gln

1395
1400
1405

Val Arg Thr Thr Ala Thr Ala Ala Phe Glu His Gln Asp Val Pro Phe 1410 1415 1420

Glu Arg Val Val Thr Ala Leu Leu Pro Arg Ser Arg Asp Leu Ser Arg 425 1430 1435 1440

Asn Pro Leu Ala Gln Leu Thr Phe Ala Leu His Ser Gln Gln Asp Leu

1445 1450 1455

Gly Lys Phe Glu Leu Glu Gly Leu Val Ala Glu Pro Val Ser Asn Lys

1460 1465 1470

Val Tyr Thr Arg Phe Asp Val Glu Phe His Leu Phe Gln Glu Ala Gly

Arg Leu Ser Gly Asn Val Ala Phe Ala Ala Asp Leu Phe Lys Pro Glu

Thr Ile Ser Asn Val Val Ala Ile Phe Phe Gln Ile Leu Arg Gln Gly

Ile Arg Gln Pro Arg Thr Pro Ile Ala Val Leu Pro Leu Thr Asp Gly

Leu Ala Asp Leu Arg Ala Met Gly Leu Leu Glu Ile Glu Lys Ala Glu

Tyr Pro Arg Glu Ser Ser Val Val Asp Val Phe Arg Lys Gln Val Ala

Ala His Pro His Ala Phe Ala Val Val Asp Ser Ala Ser Arg Leu Thr

Tyr Ala Asp Leu Asp Arg Gln Ser Asp Gln Leu Ala Thr Trp Leu Gly

Arg Arg Asn Met Thr Ala Glu Thr Leu Val Gly Val Leu Ala Pro Arg

Ser Cys Gln Thr Val Val Ala Ile Leu Gly Ile Leu Lys Ala Asn Leu

Ala Tyr Le	u Pro Leu Asp V	Val Asn Cys	Pro Thr Ala	Arg Leu Gln Thr
163	5	1640	1	645
	•	•		
Ile Leu Sei	r Thr Leu Asn A	rg His Lys	Leu Val Leu I	eu Gly Ser Asn
1650	16	55	1660	•
	•	•		
Ala Thr Thr	Pro Asp Val G	In Ile Pro	Asp Val Glu L	eu Val Arg Ile
665	1670	•	1675	1680
				· -
Ser Asp Ile	Leu Asp Arg Pr	o Ile Asn G	ly Gln Ala Ly	's Leu Asn Gly
•	1685	16	90	1695

His Thr Lys Ser Asn Gly Tyr Ser Lys Pro Asn Gly Tyr Thr His Leu

1705

1700

- 101 -

Lys Gly Tyr Se	r Asn Leu Asn G	ly Tyr Ser Lys	Gln Asn Gly Tyr Ala
1715	17	20	1725
Gln Leu Asn Gl	y His Arg Glu A	rg Asn Asn Tyr	Leu Asp Leu Asn Gly
1730	1735	1	740
His Ser Leu Leu	ı Asn Gly Asn S	er Asp Ile Thr	Thr Ser Gly Pro Ser
745	1750	1755	1760
		-	
Ala Thr Ser Leu	Ala Tyr Val I	le Phe Thr Ser (Gly Ser Thr Gly Lys
	1765	1770	1775
·			•
			le Arg Leu Ala Lys

Lys Asn Arg Ile Ile Ser Arg Phe Pro Ser Val Ala Lys Val Ala His 1795 1800 1805

Leu Ser Asn Ile Ala Phe Asp Ala Ala Thr Trp Glu Met Phe Ala Ala 1810 1815 1820

Leu Leu Asn Gly Gly Thr Leu Val Cys Ile Asp Tyr Met Thr Thr Leu
825 1830 1835 1840

Asp Ser Lys Thr Leu Glu Ala Ala Phe Ala Arg Glu Gln Ile Asn Ala 1845 1850 1855

Ala Leu Leu Thr Pro Ala Leu Leu Lys Gln Cys Leu Ala Asn Ile Pro 1860 1865 1870 Thr Thr Leu Gly Arg Leu Ser Ala Leu Val Ile Gly Gly Asp Arg Leu

Asp Gly Gln Asp Ala Ile Ala Ala His Ala Leu Val Gly Ala Gly Val

Tyr Asn Ala Tyr Gly Pro Thr Glu Asn Gly Val Ile Ser Thr Ile Tyr

Asn Ile Thr Lys Asn Asp Ser Phe Ile Asn Gly Val Pro Ile Gly Cys

`Ala Ile Ser Asn Ser Gly Ala Tyr Ile Thr Asp Pro Asp Gln Gln Leu

Val Pro Pro Gly Val Met Gly Glu Leu Val Val Thr Gly Asp Gly Leu

Ala Arg Gly Tyr Thr Asp Pro Ala Leu Asp Ala Gly Arg Phe Val Gln

1980.

Ile Met Ile Asn Asp Lys Ala Val Arg Ala Tyr Arg Thr Gly Asp Arg

Ala Arg Tyr Arg Val Gly Asp Gly Gln Ile Glu Phe Phe Gly Arg Met

Asp Gln Gln Val Lys Ile Arg Gly His Arg Ile Glu Pro Ala Glu Val

Glu Arg Ala Ile Leu Asp Gln Asp Ser Ala Arg Asp Ala Val Val

Ile Arg His Gln Glu Gly Glu Glu Pro Glu Met Val Gly Phe Val Ala

Thr His Gly Asp His Ser Ala Glu Gln Glu Glu Ala Asp Asp Gln Val

Glu Gly Trp Lys Asp Phe Phe Glu Ser Asn Thr Tyr Ala Asp Met Asp

Thr	· Ile Gly	Gln Ser	Ala Ile	Gly Asn	Asp P	he Thr	Gly Trp	Thr	Ser
		2100		2105			2110		
•									
Met		Gly Ser		Asn Lys	Ala G	lu Met	Gln Glu	Trp L	.eu
	2115		2	120		2	125		
Asp	Asp Thr	Met Arg 1	Thr Leu L	eu Asp	Gly Gl	n Ala F	ro Gly F	lis V	al
2	2130		2135			2140			
Leu	Glu Ile	Gly Thr G	ly Ser G	ly Met V	Val Le	u Phe A	sn Leu G	ly Al	a
145			50		2159			216	0
			•						
Gly :	Leu Gln :	Ser Tyr V	al Glv Le	en Glu P	ro Ser	- Arg Se	er Ala A	la Th	r

Phe Val Thr Lys Ala Ile Asn Ser Thr Pro Ala Leu Ala Gly Lys Ala

Glu Val His Val Gly Thr Ala Thr Asp Ile Asn Arg Leu Arg Gly Leu

Arg Pro Asp Leu Val Val Leu Asn Ser Val Val Gln Tyr Phe Pro Thr

Pro Glu Tyr Leu Leu Glu Val Val Glu Ser Leu Val Arg Ile Pro Gly

Val Lys Arg Val Val Phe Gly Asp Ile Arg Ser His Ala Thr Asn Arg

His Phe Leu Ala Ala Arg Ala Leu His Ser Leu Gly Ser Lys Ala Thr

Lys Asp Ala Ile Arg Gln Lys Met Thr Glu Met Glu Glu Arg Glu Glu

Glu Leu Leu Val Asp Pro Ala Phe Phe Thr Ala Leu Leu Gln Gly Gln

Leu Ala Asp Arg Ile Lys His Val Glu Ile Leu Pro Lys Asn Met Arg

Ala Thr Asn Glu Leu Ser Ala Tyr Arg Tyr Thr Ala Val Ile His Val

Arg Gly Pro Glu Glu Gln Ser Arg Pro Val Tyr Pro Ile Gln Val Asn

Asp Trp Ile Asp Phe Gln Ala Ser Arg Ile Asp Arg Arg Ala Leu Leu

Arg Leu Leu Gln Arg Ser Ala Asp Ala Ala Thr Val Ala Val Ser Asn

Ile Pro Tyr Ser Lys Thr Ile Val Glu Arg His Val Val Glu Ser Leu

Asp Asn Asn Arg Glu Asn Thr His Arg Ala Pro Asp Gly Ala Ala

Trp Ile Ser Ala Val Arg Ser Lys Ala Glu Arg Cys Thr Ser Leu Ser

Val Thr Asp Leu Val Gln Leu Gly Glu Glu Ala Gly Phe Arg Val Glu

Val Ser Ala Ala Arg Gln Trp Ser Gln Ser Gly Ala Leu Asp Ala Val

Phe His Arg Tyr Asn Leu Pro Thr Gln Ser Asn Ser Arg Val Leu Ile

Gln Phe Pro Thr Glu Asp Gly Gln Thr Arg Arg Ser Ala Thr Leu Thr

Asn Arg Pro Leu Gln Arg Leu Gln Ser Arg Arg Phe Ala Ser Gln Ile

Arg Glu Gln Leu Lys Ala Val Leu Pro Ser Tyr Met Ile Pro Ser Arg

Ile Val Val Ile Asp Gln Met Pro Leu Asn Ala Asn Gly Lys Val Asp

Arg Lys Glu Leu Thr Arg Arg Ala Gln Ile Ala Pro Lys Ser Gln Ala

Ala Pro Ala Lys Pro Val Lys Gln Val Asp Pro Phe Val Asn Leu Glu

Ala Ile Leu Cys Glu Glu Phe Ala Glu Val Leu Gly Met Glu Val Gly

Val Asn Asp His Phe Phe Gln Leu Gly Gly His Ser Leu Leu Ala Thr

Lys Leu Val Ala Arg Leu Ser Arg Arg Leu Asn Gly Arg Val Ser Val

Arg Asp Val Phe Asp Gln Pro Val Ile Ser Asp Leu Ala Val Thr Leu

Arg Gln Gly Leu Thr Leu Glu Asn Ala Ile Pro Ala Thr Pro Asp Ser

Gly Tyr Trp Glu Gln Thr Met Ser Ala Pro Thr Thr Pro Ser Asp Asp

Met Glu Ala Val Leu Cys Lys Glu Phe Ala Asp Val Leu Gly Val Glu

Val Ser Ala Thr Asp Ser Phe Phe Asp Leu Gly Gly His Ser Leu Met

Ala Thr Lys Leu Ala Ala Arg Ile Ser Arg Arg Leu Asp Val Pro Val

`705

Ser Ile Lys Asp Ile Phe Asp His Ser Val Pro Leu Asn Leu Ala Arg

Lys Ile Arg Leu Thr Gln Ala Lys Gly His Glu Ala Thr Asn Gly Val

Gln Ile Ala Asn Asp Ala Pro Phe Gln Leu Ile Ser Val Glu Asp Pro

Glu Ile Phe Val Gln Arg Glu Ile Ala Pro Gln Leu Gln Cys Ser Pro

Glu Thr Ile Leu Asp Val Tyr Pro Ala Thr Gln Met Gln Arg Val Phe

Leu Leu Asn Pro Val Thr Gly Lys Pro Arg Ser Pro Thr Pro Phe His

2805 2810

2815

Ile Asp Phe Pro Pro Asp Ala Asp Cys Ala Ser Leu Met Arg Ala Cys

2820 2825 2830

Ala Ser Leu Ala Lys His Phe Asp Ile Phe Arg Thr Val Phe Leu Glu

2835 2840 2845

Ala Arg Gly Glu Leu Tyr Gln Val Val Leu Lys His Val Asp Val Pro

2850 285.5 2860

Ile Glu Met Leu Gln Thr Glu Glu Asn Ile Asn Ser Ala Thr Arg Ser

Phe Leu Asp Val Asp Ala Glu Lys Pro Ile Arg Leu Gly Gln Pro Leu

Ile Arg Ile Ala Ile Leu Glu Lys Pro Gly Ser Thr Leu Arg Val Ile

Leu Arg Leu Ser His Ala Leu Tyr Asp Gly Leu Ser Leu Glu His Ile

Leu His Ser Leu His Ile Leu Phe Phe Gly Gly Ser Leu Pro Pro

Pro Lys Phe Ala Gly Tyr Met Gln His Val Ala Ser Ser Arg Arg Glu

945 2950

Gly Tyr Asp Phe Trp Arg Ser Val Leu Arg Asp Ser Ser Met Thr Val

Ile Lys Gly Asn Asn Asn Thr Thr Pro Pro Pro Pro Gln Gln Gln

Ser Thr Pro Ser Gly Ala His His Ala Ser Lys Val Val Thr Ile Pro

Thr Gln Ala Asn Thr Asp Ser Arg Ile Thr Arg Ala Thr Ile Phe Thr

025	3030		3035	3040	
Val Phe Gly	Arg Thr Val Se 3045	r Gly Arg Gl 305		Leu Ala His 3055	
·	le Gly Pro Cys	•			
	60 rg Gly The The	His His Ara		3070	
3075		3080	Arg Glu Leu Leu Arg Gl 3085		

Gln Glu Gln Tyr Leu Asn Ser Leu Ala Phe Glu Thr Leu Gly Tyr Asp

0 3095

3090

Thr Ala Cys Ala Leu Met Leu Ala Lys Glu Asp Asn Ser Ser Asp Val

Glu Ile Lys Ala His Cys Thr Asp Trp Pro Asp Val Pro Ala Thr Ala 105 3110 3115 3120

Ser Phe Gly Cys Cys Ile Val Tyr Gln Asn Phe Asp Ser His Pro Asp

3130

3135

3125

Ser Arg Val Glu Glu Gln Arg Leu Gln Ile Gly Val Leu Ser Arg Asn 3140 3145 3150

Tyr Glu Ala Ile Asn Glu Gly Leu Val His Asp Leu Val Ile Ala Gly 3155 3160 3165

Glu Ser Glu Pro Asp Gly Asp Asp Leu Arg Val Thr Val Val Ala Asn 3170 3175 3180 Arg Arg Leu Cys Asp Glu Glu Arg Leu Lys Arg Met Leu Glu Glu Leu

185

3190

3195

3200

Cys Gly Asn Ile Arg Ala Leu Ala Leu Val

3205

3210

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 3

tggacnwsna tgtaygaygg

- 20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

` <400> 4

<210> 5

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 5

gcggaattaa ccctcactaa agggaacgaa

<210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 6

gcgtaatacg actcactata gggcgaagaa

30

<210> 7

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 7

agcatcggat cctaacaatg ggcgttgagc agcaagccct a

41

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 8

tttgcttcgt actcgggtcc t

21

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

` <223> Description of Artificial Sequence:synthetic DNA

<400> 9

gcatcgcgat actagagaag

20

<210> 10

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 10 .

agcatcgaat tcggatccct aaaccaacgc caaagcccga at

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 11

tgatatgctg gagcttccct

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthet.ic DNA

<400> 12

gcacaacctc tttccaggct

20

<210> 13

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 13

agcatcggat cctaacaatg tcaaacatgg caccactccc ta

42


[Brief description of the drawings]


[Figure 1]

Figure 1 shows a construction procedure of plasmid pABP/PFsyn.

[Figure 2]

Figure 2 schematically shows the SDS-PAGE result of the expression, in a gene-introduced strain, of the cyclic depsipeptide synthetase which is the translation product of the gene of the present invention.





[TTTLE OF DOCUMENT] ABSTRACT
[ABSTRACT]

[OBJECT OF INVENTION]

To provide a method for producing a cyclic depsipeptide having anthelmintic activity, a cyclic depsipeptide synthetase gene capable of improving productivity of the substance PF1022 and a protein coding therefor, a recombinant vector comprising the gene, and a substance PF1022-producing microorganism and substance PF1022 into which the recombinant vector is introduced.

[MEANS FOR ATTAINING THE OBJECT]

A gene encoding a cyclic depsipeptide synthetase enhancing the biosynthesis of the substance PF1022 is isolated from a substance PF1022-producing microorganism. A recombinant vector is prepared by the substitution of the promoter and terminator of the gene with those of a foreign gene utilizable for expression augmentation, and then the recombinant vector is introduced into the substance PF 1022-producing microorganism, whereby the improvement in productivity of the substance PF 1022 was attained.

[SELECTED FIGURE]

None